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Patient-centeredness has gained favor in recent years. Drug development researchers
increasingly acknowledge that patient preferences can contribute valuable informa-
tion to decision-making. The importance of incorporating patient preferences is
underscored for rare disease populations in which clinicians and researchers have
limited experience with the condition and the disease experience is best understood
by patients. This dissertation aims to measure preferences among caregivers and
patients with Duchenne muscular dystrophy (DMD).
Methods
This body of work is based on a two online surveys intended for caregivers and
patients with DMD. Survey respondents were recruited via a patient registry and
snowball sampling. The surveys were designed using a community-engaged ap-
proach and included best-worst scaling (BWS) case 1, case 2 and conjoint-analysis.
The main analytic methods included latent class analysis, mixed logistic regression
and conditional logistic regression.
Results
Chapter 3 demonstrates a successful process for community engagement in survey
development that affected eligibility criteria, attribute refinement, and revealed the
delicate nature of mapping clinical trial endpoints to meaningful survey objects.
Chapter 4 findings indicate that caregivers and patients do not differ in their prior-
ities for signs and symptoms to be targeted by therapeutic interventions. However,
priority heterogeneity does exist and may be related to unobserved characteristics.
Chapter 5 findings reveal patients are willing to accept significant risk in order to
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have the benefit of moderate improvements in pulmonary decline. Finally, method-
ological findings in Chapter 6 indicate that conjoint analysis combined with BWS
provides policy-relevant information about the intention to use therapy and serves
to validate the BWS method.
Conclusions
This research contributes to the overall body of knowledge around patient prefer-
ences in DMD and as a result may improve the usefulness of future drug develop-
ment. It also measures patient preferences for a pulmonary benefit, information
that will be incorporated into regulatory review. There are implications for the
broader rare disease community: this dissertation demonstrates a model for how to
undergo this research and underscores the importance of preference work to meet
the unique needs of the rare disease community.
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1.1 Patient-centered benefit-risk assessment
Patient-centered benefit-risk (PCBR) assessment is the increasingly favored view
of incorporating patient preference information into regulatory decision-making.
Patient preference information is generally concerned with how patients and fam-
ilies make decisions about their health and healthcare, but in a PCBR context,
patient preference information refers specifically to how patients make decisions
about new technologies such as drugs or medical devices. The aim of PCBR is to
understand how patients value benefits and risks and how they consider benefit-
risk tradeoffs, including quantifying risk tolerance, maximum acceptable risk, and
minimum required benefit.
When a New Drug Application is submitted to the FDA, a team of scientists,
including physicians, statisticians, toxicologists, pharmacologists, and chemists re-
view the data and proposed labeling to establish if the drug’s benefits outweigh its
known risks. FDA considers whether or not the drug is safe and effective in its
proposed use and whether the benefits outweigh the risk [1]. Only those sitting
around the table at the time of the decision are privy to the intricacies of the pro-
cess. The benefit-risk framework used to make the decision includes five decisions
factors: 1) analysis of condition, 2) current treatment options, 3) benefit, 4) risk
and 5) risk management [2]. The first two factors are not drug-specific consider-
ations, but are considerations for the therapeutic area. The last three factors are
drug-specific considerations. All the factors are dynamic and can be updated as
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new information becomes available. For the therapeutic area considerations, this
information represents the current state of knowledge regarding the condition and
available therapies and changes as new drugs enter or exit the market and as new
information about the disease becomes available. For the drug-specific considera-
tions, this can be updated as new information about benefits and risks becomes
available throughout the drug lifecycle (i.e. post-approval).
Patient preferences are noticeably absent from this regulatory benefit-risk frame-
work. Historically, patient involvement in the regulatory process has been minimal.
A patient representative, or in some cases a few representatives, have been included
on the expert advisory panels. However, this is limited to qualitative data that is
not necessarily representative of the breadth of patient perspectives. It is unknown
how this information, if at all, is incorporated in the regulatory decision-making
process. Details about traditional regulatory benefit-risk assessment are elusive
[3-4]. PCBR is a logical extension of benefit-risk assessment in which the patient’s
perspective is considered in evaluation of the safety and efficacy of a new technology.
1.2 History of patient-centered drug development
In the United States, the Food and Drug Administration (FDA) is a powerful reg-
ulatory agency that authorizes drugs and medical devices to be legally marketed
after the agency deems them safe and efficacious [5]. In this way, the FDA serves
as a very powerful gatekeeper to the pharmaceutical marketplace. The Prescrip-
tion Drug User Fee Act (1992) provided a supplemental revenue source for the
agency by authorizing the FDA to charge pharmaceutical companies fees. Pa-
tient perspectives were first incorporated into drug development when PDUFA was
reauthorized by Congress in 1997 as part of the Food and Drug Administration
Modernization Act; it aimed to facilitate better communications between pharma-
ceutical companies and patient advocacy groups. Patients weren’t systematically
and earnestly included until the fifth reauthorization in 2012, which was included in
Food and Drug Administration Safety and Innovations Act (FDASIA). The Pre-
scription Drug User Fee Amendments of 2012 (PDUFA V) called for upgrading
benefit/risks assessments and more patient perspectives in the drug review pro-
cess. The Secretary was charged with developing and implementing strategies to
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solicit patient perspectives during the development process and to consider those
preferences during regulatory discussions by “fostering participation” of patient
representatives [6].The expansion of PCBR assessment also includes consideration
of current treatment options as well as the severity of the condition, but does not
include patient preferences.
Since PDUFA V, and since the ACA has more generally directed the country
towards patient-centered healthcare, US regulatory agencies have made a concerted
effort to understand the perspective of the patient. The Center for Drug Evaluation
and Research (CDER), the office within the FDA responsible for regulating drugs,
launched the Patient Focused Drug Development (PFDD) initiative. This initiative
offers a systematic way to collect information about the patient’s perspectives on
disease severity, available treatments, and how drugs can better meet their needs.
It has conducted or plans to conduct 20 meetings over the course of 5 years, each
focused on a specific disease area. Following each meeting, a ”Voice of the Patient
Report” summarizes the content. A concerted effort was made to target disease
areas that are 1) chronic, symptomatic and affect functioning, 2) for which aspects
of the disease are not fully captures in clinical trials, 3) diseases with limited or no
current therapies, and 4) diseases with severe impact on identifiable subpopulations
such as children or the elderly. Recognizing what a small percentage of diseases
would be covered by only 20 meetings, the FDA also invited outside organizations to
organize externally led PFDD meetings using the FDA model [7]. Similar efforts
are occurring throughout the European Medicine Agency (EMA), the European
counterpart to the FDA [8].
Concurrently, the Center for Devices and Radiological Health (CDRH), the of-
fice of the FDA responsible for regulating medical devices and radiation-emitting
products, launched the Patient Preference Initiative to identify and develop meth-
ods for assessing patient preferences of benefit and risk related to specific device
types and specific illnesses and conditions. Although both CDER and CDRH are
both playing a role in shaping patient-focused drug development, many of the ad-
vances specific to PCBR have occurred within CDRH and the Center for Biologics
Evaluation and Research (CBER), the branches of the FDA responsible for the
approval of all medical devices, biologics and related products. CDRH and CBER
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published a draft guidance on benefit-risk in 2012 stating that FDA reviewers may
consider patients perspectives when such information is available [9]. A later docu-
ment in 2015 expanded on this to advise what patient preference information may
be used by FDA and highlighted its importance for preference-sensitive decisions in
which there is significant uncertainty and patients’ views differ considerably from
those of researchers and clinicians [10]. This guidance document also acknowledges
the variation in patient preferences and enumerates how and when the FDA might
consider patient preference information during its review process. The FDA ac-
knowledges that quantitative patient preference assessment is an evolving research
area. Furthermore, in early 2015, the CDRH published its first preference study
intended to inform regulatory decision-making. This included presenting relative
value for attributes of weight-loss devices and a tool to estimate minimal acceptable
benefit and maximum acceptable risk [11].
To date, the FDA has not provided detailed instructions on how device de-
velopers should collect and use this information. To that end, the Medical De-
vice Innovation Consortium (MDIC), a public-private partnership made up of key
stakeholders, has developed a framework for incorporating patient preference infor-
mation regarding benefit and risk into regulatory assessment of new technologies
[3]. The framework report released in May 2015 provides background on PCBR,
discusses the value of PCBR in the regulatory context, provides guidance on cir-
cumstances in which PCBR is valuable, appropriating timing for PCBR’s use in
the development lifecycle, and offers advice on how to collect and use preference
information including a catalog of appropriate methods.
1.3 PCBR for rare diseases
As the recipients of treatment, all patients have a distinctive role in benefit-risk
assessment and regulatory decision-making. However, patients with rare diseases
have a particularly important role to play. Current PCBR information sources
highlight rare diseases as an appropriate context for patient preference informa-
tion because treatment choices are laden with preference-sensitive decisions due to
high levels of uncertainty. Furthermore, reviewers’ limited clinical experience with
rare diseases means that patient preferences likely differ significantly from those
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of reviewers and clinicians and therefore patient preference information may be
highly relevant [3]. Additionally, in the rare disease context patient preferences are
imperative to either confirm or contradict assumptions about extremely high risk-
tolerance thresholds in the face of high mortality, severe morbidity and a scarcity
of treatment options.
1.4 Duchenne muscular dystrophy
Duchenne muscular dystrophy (DMD) is a rare, life-shortening, inherited neuro-
muscular disorder that occurs in 1.3-2.9 per 10,000 males [11-12]. Onset occurs
early in life with symptoms first appearing in early infancy and diagnosis typically
occurring around age 5, when motor function typically develops [14-15]. DMD is
characterized primarily by progressive muscular weakness and loss of ambulation
in their teen years [14,16]. It also involves expected pulmonary decline [17-21]. It
ultimately results in premature death in the boy’s second and third decade most fre-
quently as a result of respiratory failure from pneumonia with cardiac involvement
[14-15]. There are currently no FDA-approved therapies for DMD, and the gold
standard for treatment relies on off-label use of corticosteroids, which has shown
to have some benefits with regards to slowing the loss of muscle loss, delaying loss
in ambulation by 2-5 years, improving cardiopulmonary function and enhancing
quality of life [14, 22-24].
This disease makes for an interesting context in which to study patient centered
benefit-risk assessment because patient and caregivers are actively involved in ad-
vocating for accelerated drug approvals, encouraging regulatory permissiveness and
demanding access [25-27]. There are also many preference sensitive decisions due
to significant care-related burden, financial burden, the vulnerability of a pediatric
population and caregivers often being the primary decision-maker, and of course
the natural history of the disease [27-30]. Finally, DMD is an ideal population
for this research because the community’s advocacy leadership have been active




1. Food and Drug Administration (US). New Drug Application (NDA): Introduc-
tion. [Internet]. Silver Spring, MD (US): 2016. [cited 2016 Mar 18]. Available from:
www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedand
Approved/ApprovalApplications/NewDrugApplicationNDA/default.htm.
2. Food and Drug Administration (US). Structured Approach to Benefit-Risk As-
sessment in Drug Regulatory Decision-Making. Draft PDUFA V Implementation
Plan - February 2013. Fiscal Years 2013-2017. [Internet]. Silver Spring, MD (US):
2013. [cited 2016 Mar 18]. Available from: www.fda.gov/downloads/
ForIndustry/UserFees/PrescriptionDrugUserFee/UCM329758.pdf.
3. Medical Device Innovation Consortium (MDIC). 2015. Medical Device Innova-
tion Consortium (MDIC) Patient Centered Benefit-Risk Project Report: A Frame-
work for Incorporating Information on Patient Preferences Regarding Benefit and
Risk into Regulatory Assessments of New Medical Technology.
4. Thaul S. How FDA approves drugs and regulates their safety and effectiveness.
Congressional Research Services Report for Congress. [Internet]. Washington, DC
(US): June 25, 2012. [cited 2016 Mar 18]. Available from: www.fas.org/sgp/crs/
misc/R41983.pdf.
5. Carpenter D. Reputation and power: Organizational image and pharmaceutical
regulation at the FDA. Princeton, NJ: Princeton University Press. 2010.
6. Food and Drug Administration Safety and Innovation Act (FDASIA), Pub. L.
112-144, 126 Stat. 993, codified as amended at 21 U.S.C. §301 (2012).
7. Food and Drug Administration (US). 2015. Externally-led patient-focused drug
development meetings. [Internet]. Silver Spring, MD (US): 2015. [cited 2016 Mar
18]. Available from: www.fda.gov/ForIndustry/UserFees/PrescriptionDrug
UserFee/ucm453856.htm.
8. European Medicines Agency (UK). The patient’s voice in the evaluation of
medicines: How patients can contribute to assessment of benefit and risk. [Inter-
net] London, UK: 2013. [cited 2016 Mar 18]. Available from: www.ema.europa.
eu/docs/en_GB/document_library/Report/2013/10/C500153276.pdf.
9. Food and Drug Administration (FDA). 2012. Guidance for industry and Food
and Drug Administration Staff: factors to consider when making benefit-risk de-
terminations in medical device premarket approval and de novo classifications. De-
partment of Health and Human Services Food and Drug Administration, Center
for Devices and Radiological Health, Center for Biologics Evaluation and Research.
Rockville, MD.
10. Food and Drug Administration (FDA). 2015. Patient Preference Information
- Submission, Review in PMAs, HDE Applications, and De Novo Requests, and
Inclusion in Device Labeling: Draft Guidance for Industry, Food and Drug Admin-
istration Staff, and Other Stakeholders. Department of Health and Human Services
Food and Drug Administration, Center for Devices and Radiological Health, Cen-
ter for Biologics Evaluation and Research. Rockville, MD.
11. Ho MP, Gonzalez JM, Lerner HP, Neuland CY, Whang JM, McMurry-Heath
M. Incorporating patient-preference evidence into regulatory decision making. Surg
Endosc. 2015;9(10):2984-93.
12. Centers for Disease Control and Prevention (CDC). Prevalence of Duchenne/
6
Becker muscular dystrophy among males aged 5-24 years-four states, 2007. MMWR
Morb Wkly Rep. 2009;58:1119-22.
13. Emery AE. Population frequencies of inherited neuromuscular diseases-a world
survey. Neuromuscul Disord. 1991;1:19-29.
14. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al.
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis,
and pharmacological and psychosocial management. Lancet Neurol. 2010;9:77-93.
15. Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K. Sur-
vival in Duchenne muscular dystrophy: improvements in life expectancy since 1967
and the impact of home nocturnal ventilation. Neuromuscul Disord. 2002;12(10):926-
9.
16. Flanigan KM. Duchenne and Becker muscular dystrophies. Neurol Clin.
2014;32(3):671-88.
17. Inkley SR, Oldenburg FC, Vignos PJ Jr. Pulmonary function in Duchenne
muscular dystrophy related to stage of disease. Am J Med. 1974;56:297-306.
18. Rideau Y, Jankowski LW, Grellet J. Respiratory function in the muscular dys-
trophies. Muscle Nerve. 1981;4(2):155-64.
19. McDonald CM, Abresch RT, Carter GT, et al. Profiles of neuromuscular dis-
eases. Duchenne muscular dystrophy. Am J Phys Med Rehabil. 1995;74:S70-92.
20. Tangsrud S, Petersen IL, Lodrup Carlsen KC, Carlsen KH. Lung function in
children with Duchenne’s muscular dystrophy. Respir Med. 2001;95:898-903.
21. Kohler M, Clarenbach CF, Boni L, Brack T, Russi EW, Bloch KE. Quality of
life, physical disability, and respiratory impairment in Duchenne muscular dystro-
phy. Am J Respir Crit Care Med. 2005;172:1032-6.
22. Biggar WD, Harris VA, Eliasoph L, Alman B. Long-term benefits of Deflaza-
cort treatment for boys with Duchenne muscular dystrophy in their second decade.
Neuromuscul Disord. 2006;16:249-55.
23. Angelini C. The role of corticosteroids in muscular dystrophy: a critical ap-
praisal. Muscle Nerve. 2007;36:424-35.
24. Bushby K, Muntoni F, Urtizberea A, Hughes R, Griggs R. Report on the
124th ENMC International Workshop. Treatment of Duchenne muscular dystro-
phy; defining the gold standards of management in the use of corticosteroids 2-4
April 2004, Naarden, The Netherlands. Neuromuscul Disord. 2004;14(8):526-34.
25. Franson TR, Peay H. Benefit-risk assessments in rare disorders: the case for
therapeutic development in Duchenne muscular dystrophy as the prototype for new
approaches. [Internet]. Parent Project Muscular Dystrophy, Hackensack, NJ (US):
2014. [cited 2014 Apr 28]. Available from: www.parentprojectmd.org/BR.
26. Genetic Alliance UK (UK). New medicines for serious conditions: weighing the
risks and benefits. The verdict of a jury of patients. [Internet]. London, UK: 2012.
[cited 2014 Mar 1]. Available from: www.geneticalliance.org.uk/docs/citizens-jury-
report.pdf.
27. McNeil DE, Davis C, Jillapalli D, Targum S, Durmowicz A, Cote TR. Duchenne
muscular dystrophy: drug development and regulatory considerations. Muscle
Nerve. 2010;41(6):740-5.
28. Larkindale J, Yang W, Hogan PF, Simon CJ, Zhang Y, Jain A, et al. Cost of
illness for neuromuscular diseases in the US. Muscle Nerve. 2014;49:431-8.
29. Ouyang L, Grosse SD, Fox MH, Bolen J. A national profile of health care and
7
family impacts of children with muscular dystrophy and special health care needs
in the United States. J Child Neurol. 2012;27:569-76.
30. Ouyang L, Grosse SD, Kenneson A. Health care utilization and expenditures
for children and young adults with muscular dystrophy in a privately insured pop-
ulation. J Child Neurol. 2008;23:883-8.
31. Furlong, P, Bridges JFP, Charnas L, Fallon JR, Fischer R, Flanigan KM, et
al. How a patient advocacy group developed the first proposed draft guidance
document for industry for submission to the U.S. Food and Drug Administration.




Stated-preference methods are a research method to objectively and scientifically
measure consumer preferences based on hypothetical scenarios. These methods
contrast revealed preferences in which consumer behavior is observed in real mar-
kets. A key disadvantage of revealed preferences is that its use is limited to existing
goods and services. Stated-preference methods on the other hand, are designed to
understand how consumers may behave toward a hypothetical good and are there-
fore ideal for incorporating patient preferences into patient-centered drug develop-
ment - a context in which regulators have to weigh benefits, risks, and their relative
importance for a hypothetical good under a great deal of uncertainty.
2.1 Best-worst scaling
In evaluating trade-offs, choice-based preference measurement such as conjoint anal-
ysis are useful. Conjoint analysis is designed to measure choice behavior. Discrete
choice experiments (DCE) has been the traditional technique for preference elici-
tation and widely used in healthcare [1-2]. Best-worst scaling was introduced by
Finn and Louviere in 1992 and its formal statistical and theoretical properties were
proven by Marley and Louviere in 2005 [3-4]. Although McIntosh and Louviere
first introduced BWS to healthcare research in 2002, and it has become increas-
ingly used in healthcare, it is still lesser-known compared to other choice-based
approaches [5-8]. A full catalog of stated-preference methods for assessing patient
preferences for patient-centered benefit-risk are available [9].
Best-worst scaling (BWS) is a form of conjoint analysis that presents survey
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respondents with an attribute set (or attributes and levels set) of three or more
items from which the respondent identifies the best and worst items [10]. The
attribute set can be thought of as characteristics of a good. BWS in particular,
and choice-based modeling in general, is an application of consumer theory in which
utility is derived from a particular bundle of characteristics rather than from a good
itself [11]. The underlying assumptions of BWS are that that the choices themselves
represent the extremes of a latent, subjective continuum [10].
There are three types of BWS: object case, profile case, and multi-profile case
[3,6]. In the object case (case 1) respondents evaluate a list of independent objects,
similar to how one evaluates a ranking scale [6]. The design is intended to assess
relative preferences for a series of objects. Examples of its use in healthcare include
investigating opinions about food supply policy and to guide health reform in Aus-
tralia [3,13]. In the profile case (case 2) respondents evaluate a single profile at a
time, made up a series of attributes with different levels assigned, and choose the
best and worst attribute/level combinations from within that profile [6,14]. In the
multi-profile case (case 3), respondents evaluate sets of multiple profiles together at
a time and choose the best and worst overall profile [6,15]. BWS case 1 and 2 are
the dominant variants in healthcare with applications that include eliciting utility
weights, evaluating treatments and interventions, measuring workforce preferences,
and identifying criteria for policy decisions such as budget allocation and priority-
setting [8]. The enclosed studies concern BWS case 1 and 2. For either type, the
response pattern can be analyzed to estimate the relative importance among the
attributes (case 1) or attributes and levels (case 2).
2.2 Theory
BWS as probabilistic discrete choice models have been well-established [4,16].
These models, based in random-utility theory, are consistent with neoclassical eco-
nomic theory [11,17-19]. Random-utility theory suggests that the decision process
is considered to be deterministic and the utilities are stochastic. Economists in-
terpret the probabilistic nature of the models such that researchers are unable to
measure all factors that impact the choice. An alternative theory for discrete choice
modeling suggests the decision process is random and the utilities are determinis-
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tic. The psychology discipline subscribes to this fixed utility theory and interprets
the probabilistic natures of the models as a result of inconsistencies in human
decision-making [20]. Summaries outlining how the two disciplines approach the
decomposition of the probabilistic process and its application to BWS have been
published elsewhere [10]. Regardless of discipline, as researchers, we must simplify
the complexity of human decision-making process with models.
Max-difference (paired) models assume that individuals consider all of the pos-
sible pairs of best and worst and choose the pair that maximizes the difference
between them. Parameters and log-likelihood can be correctly estimated using a
standard conditional (multinomial) logistic regression command (implemented via
the paired MNL method). Marginal models consider the best and worst choices
separately; as such, they may be considered to be more realistic than paired ones.
Choices can be made simultaneously or sequential. In this dissertation sequential
best-worst scaling is used, which introduces a trivial error to the log-likelihood but
is more consistent with how the data are collected [6]. This analysis relies on an
essential assumption that the choice of the best and worst item represents the far-
thest different between the degree of importance among any item on an underlying
ranking of item importance [21]. Econometrics operationalization of BWS data in
a random utility model parallels that of a traditional DCE [6,22]. In acknowledge-
ment that the extreme choices on either end of latent, subjective continuum are
not necessarily equivalent to a choice being considered acceptable or unacceptable
[10], a second-order opt out question to measure actual intention to use treatments
is incorporated into the experiment as well.
Regardless of type, collecting two responses (best and worst choice) elicits more
data about the respondent’s preferences for items than can be obtained through
conjoint analysis, which asks respondents to accept or reject a given commodity
under a set of conditions [23]. BWS places greater emphasis on item importance,
whereas conjoint analysis emphasizes trade-offs and more closely represents a real
decision [24]. Furthermore, best-worst scaling has the added advantage of its abil-
ity to estimate conditional attribute importance, which is the estimated utility
associated with a particular attribute, with no reference to associated levels.
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Background We provide a community-engaged process to inform the design of a
stated preferences experiment. The process involves integrating patients and care-
givers of people with Duchenne/Becker muscular dystrophy, advocates, clinicians,
and the sponsor in conceptualizing and developing a benefit-risk survey based on
phase III trial results.
Methods Our community engagement process for development of a stated-preference
survey includes a set of five guiding principles with foundations in the principles
of community-engaged research. Engagement efforts were carried out through an
informal network of 3 committees. Members of leadership, stakeholder and review
committees comprised of patients, caregivers, clinicians, advocacy leadership, and
industry representatives.
Results Committee members participated in 15 hours of formal engagement in-
cluding interviews and conference calls that ranged from 45 - 90 minutes, plus
additional less-formal ad hoc communication. Committees were comprised of 20
individuals across 3 committees including adults with Duchenne muscular dystro-
phy (n=6), parents of children with Duchenne muscular dystrophy (n=6), clinicians
(n=3), members of research and advocacy organizations (n=4), and an industry
representative (n=1). Community engagement informed attribute selection, sur-
vey length, word choice, and eligibility criteria. Challenges in the process included
managing diverse stakeholder perspectives, time requirements, and the inherent
tension between outcomes used in clinical trials versus attributes that correspond
to patient and family-relevant outcomes.
Conclusions We demonstrate how community engagement can successfully influ-
ence study design to support the design of a relevant survey instrument that is
ethical, acceptable, meaningful to the community, and enhances patient-centered
benefit-risk assessment for regulatory decision-making.
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3.2 Background
Patient-centered benefit-risk assessment (PCBR) is the science of assessing pa-
tient preferences regarding benefit- risk tradeoffs. Applied to a regulatory context,
PCBR refers to using information about how patients consider benefit-risk tradeoffs
in regulatory decision-making. Historically, the U.S. Food and Drug Administra-
tion (FDA) has considering primarily the regulatory and researcher perspectives in
benefit-risk assessment for approvals. Recently, however, there has been increas-
ing recognition of the value of the patient and caregiver perspectives in regulatory
decision-making. In 2012, as part of the FDA Safety and Innovation Act (FDA-
SIA) the agency committed to further development of its Benefits Risk Assessment
Framework, integration of the framework into the review process, and established
a five-year Patient Focused Drug Development program intended to increase stake-
holder involvement in regulatory processes [1-2]. Evidence of a shifting paradigm
in favor of patient-centeredness is further reflected in FDA guidance documents
that represent current thinking and serve as a set of recommendations for industry
and regulators. A 2012 guidance from the Centers for Devices and Radiological
Health (CDRH) listed patient preferences among factors to consider when mak-
ing benefit-risks determinations in medical device approvals [3]. In 2013, the FDA
invited Parent Project Muscular Dystrophy (PPMD), an advocacy organization fo-
cused on finding a cure for Duchenne and Becker Muscular Dystrophy (DBMD), to
write the first patient-advocacy-initiated draft guidance [4]. In June 2014, PPMD
submitted a draft guidance to the FDA to help accelerate drug development and
review of DMD therapies [5]. One year later, the FDA released its own guidance on
DMD and related disorders, which included a statement that regulatory decisions
would consider patient and caregiver risk tolerance in light of the life threatening
nature of the condition [6].
PCBR studies require methods that produce representative, scientific data to
quantify preferences and directly inform regulatory review [7]. PCBR stakehold-
ers have cataloged methods, published checklists and developed frameworks for
using these methods [8-9], but less attention has been paid to when and how to
include patients and other stakeholders. The PPMD draft guidance recommends
industry sponsors engage with patients and families early in drug development and
16
partner with advocacy organizations to better understand meaningful benefits and
risk tolerance [5]. Furthermore, the guidance recommends that sponsors engage
in community-centered research, including patient-centered efforts, to obtain pref-
erence information if it does not already exist, and use that data to inform FDA
submissions [5].
Stated-preference methods are survey-based methodologies for valuation of a
non-market good, a characteristic that makes them particularly useful for PCBR
assessment [9-10]. They contrast revealed preferences studies that determine value
based on observed behavior [10-11]. Discrete-choice experiments (DCE) and best-
worst scaling (BWS), two commonly used stated-preference methods in healthcare
[12-14], require respondents to choose among hypothetical alternatives. Under the
assumption that the respondents’ choice maximizes their utility, comparison of
choices across multiple combinations of attributes and levels are used to calcu-
late the relative utility for a particular attribute [10,15]. Thus, the appropriate
specification of attributes and levels are necessary for a valid instrument.
Attribute development for a stated-preference survey is generally conducted
as a two-staged process consisting of conceptual development and refinement [16].
Conceptual development considers the list of attributes that inform the benefit-
risk tradeoff and refinement translates those attributes to lay audiences [16]. The
importance of systematic and transparent methods for attribute development in
stated-preference methods is well documented [16,17]. While experts suggest in-
corporating community members to support attribute refinement, there has been
little guidance on how to conduct and use evidence generated from such interac-
tions [8,18]. Furthermore, lack of transparency about attribute development leaves
researchers with few models to follow and less clarity in interpreting results [16,19-
20]. There is a growing body of literature that uses consensus methods for attribute
development, but this focuses on reducing long attribute lists to a manageable num-
ber in the conceptual development stage [21-24]. Consensus methods techniques
are not ideal for attribute refinement or in a pragmatic, rapid context. The limited
available guidance suggests using qualitative methods for attribute development
[16, 25-26], but only one reports a development methodology [27].
We describe a community-engaged process for study design in the Duchenne and
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Becker muscular dystrophy (DBMD) community. DBMD is a rare, neuromuscular
disease characterized primarily by muscle degeneration resulting in weakness, loss
of ambulation, and premature death [28]. We focus on attribute refinement for
a preference study designed to inform regulatory review for a therapeutic agent
that demonstrated pulmonary benefits in phase III trial results. Previous research
demonstrates the community’s willingness to accept risk for slowing the progression
of muscle weakness [29], the hallmark characteristic of DBMD, but no data existed
on preferences for pulmonary benefits. Pulmonary-focused therapeutic targets are
appealing to clinicians because deterioration in pulmonary function is one of the
primary causes of death [30-34].
The aim was to test a community-engaged process for stated-preference survey
development to inform regulatory benefit-risk assessment. This context requires an
approach that is both pragmatic and rapid. The purpose of this paper is to describe
our context-specific approach and illustrate its use designing stated-preference in-
struments to aid regulatory benefit-risk assessment.
3.3 Methods
Process overview
We describe a community-engaged process to inform the design of a stated-preference
study and tested that approach for patients and caregivers of people with DBMD
(see Figure 3.1). Because this effort occurred in direct response to regulatory
guidance documents, an industry sponsor initiated the process by approaching an
advocacy organization to lead a scientific team. The advocacy organization orga-
nized a scientific team with relevant expertise. First, the scientific team developed
a set of guiding principles with foundations in the principles of community-engaged
research [35]. Next, appropriate sources of stakeholder variety were identified and
volunteers were purposefully recruited to represent diverse perspectives. Sufficient
stakeholder variability was particularly important because the survey targeted three
populations included teens and adults with DBMD and caregivers. The clinician
perspective was also valued given their role in facilitating treatment choice. Thus
participating stakeholders included adults with DBMD, caregivers of children of
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diverse ages, and clinicians. The trial sponsor, who funded the survey develop-
ment, was also included, with similar influence on attribute development as other
stakeholders involved in the process. A committee structure was established to
organize stakeholders around specific project goals. In addition to the scientific
team, there were leadership, stakeholder and review committees, which are de-
scribed in detail below. Finally, the scientific team defined the relevant outputs
of each committee based on how outputs would translate to desired outcomes and
ultimate impact. The goals of engagement were to inform survey design such that
the survey was ethical and acceptable, meaningful to the community, and produced
quality patient-centered benefit-risk data. The overall impact of engagement and
the survey was to identify patient and caregiver priorities regarding therapeutic
targets and enhance regulatory review with PCBR.
Guiding principles
As shown in Figure 3.1, the guiding principles were: 1) incorporating patient per-
spectives into drug development and regulatory review is worthwhile; 2) patient and
caregiver perceptions of meaningful benefits/risks may differ from researcher and
clinician perspectives; 3) the patient and caregiver community is actively engaged
and willing to participate; 4) study data belong to the patient and caregiver com-
munity; 5) all stakeholders deserve a voice in study development; and 5) regulators
are receptive to preference data.
Committee structure and goals
A leadership committee guided the entire project and reviewed all major deci-
sions informed by interactions with other stakeholders. This included advising on
inclusion and exclusion criteria, informing conceptual survey development and sub-
sequent refinement, and addressing concerns during development. The leadership
committee participated in one-on-one and group calls, and subsequently provided
input through email and in-person communications. They continue to advise on
advocacy implications of the findings and results dissemination.
The scientific team was a subset of the leadership team that executed the
project. Although all the committees were vital to the development process, the
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Figure 3.1: Community engagement process and outcomes for stated-preference
attribute development.
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scientific team was responsible for synthesizing information, making scientific deci-
sions, and confirming those decisions with the leadership team. Although informed
by the various committees, the scientific team ultimately was responsible for the
scientific integrity of the study. This information flow allowed for flexibility so that
all stakeholders could be responsive to emerging needs.
The stakeholder committee contributed to creating and refining a pool of poten-
tial treatment attributes and levels, as well as the survey language that introduced
the experiments and the attributes. Members were asked to participate in either
one-on-one or group meetings or conference calls. They also provided written feed-
back on the attribute list and responded ad hoc to questions during survey devel-
opment. Clinician and patient/caregiver interactions were conducted separately to
address slightly different topics. Clinician participants were asked how they would
describe the potential benefits and risks/burden of the therapy to their patients
based on the phase III trial data, and then to discuss non-skeletal muscle DBMD
symptoms that patients may find important as therapeutic targets. Patients and
parents were asked about their perceptions of the potential benefits and poten-
tial risks or burdens of the therapies, and then discussed DBMD symptoms that
should be prioritized as treatment targets. The conversations continued to discuss
how these may be incorporated into a survey to explore the meaningfulness of the
pulmonary benefits and how to frame risks and burdens.
Leadership and stakeholder committee members were provided with detailed
scientific reports and a lay summary of the clinical trial results. The trial was
discussed at the beginning of the first engagement. Finally, the leadership and
stakeholder committees each discussed ethical determination of inclusion criteria,
focused on a balance between allowing the broadest inclusion possible versus defin-
ing appropriate age cutoffs for a survey that includes emotionally-laden content.
The leadership and stakeholder committees comprised adults with DBMD, care-
givers, advocacy organization leadership, clinicians and a industry sponsor repre-
sentative.
The review committee participated in cognitive interviews to refine the instru-
ment. The review committee consisted of eligible survey respondents: caregivers
of people with DBMD and adults with DBMD. During the cognitive interviews,
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committee members completed the draft survey while reading aloud and sharing
stream-of-conscious reactions. Prior to each interview the scientific team identified
priority areas for input, such as potentially confusing directions, item wording, and
emotionally difficult sections. These interviews took place over Skype, a pragmatic
choice for a rare disease population that allowed the research team to benefit from
visual cues. All interviews were audio recorded and reviewed by two team mem-
bers. After the interviews, review committee members were asked to review survey
changes that resulted from their participation for final input and suggest appro-
priate ages for survey eligibility. An iterative approach to survey design was used
such that learnings from each interview were applied to the most current version
of the survey. Following the cognitive interviews, ad-hoc advice was sought from
stakeholder committee members to inform final survey language.
3.4 Results
Participants and activities
Final committee membership included 20 individuals across three committees. The
leadership committee (n=6) included a researcher with stated-preference method
expertise (n=1), advocacy organization members including leadership and community-
engagement experts (n=3), an adult with DBMD (n=1) and a parent (n=1). The
stakeholder committee (n=8) included parents (n=2), adults with DBMD (n=2),
clinicians (n=3) and an industry representative (n=1). Review committee mem-
bers (n=6) included adults with DBMD (n=3) and parents (n=3). Each committee
member served on only one committee.
Committee members represented a diverse age range of people affected by
DBMD, though all were affected with DMD (none with BMD). Parent commit-
tee members were all mothers and had at least one child with DBMD ranging from
age 5 to 22 years. Clinician members were physicians of rehabilitative medicine or
neurology (n=2) and an advanced practice nurse (n=1).
Engagement activities entailed over 15 hours of formal engagement including
15 interviews and recorded conference calls. These formal engagement efforts were
augmented with in-person conversations and email communications, with most
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stakeholders receiving at least two additional email and/or in-person requests for
additional input. Stakeholder committee members participated in one of six meet-
ings of average 46 minutes (range 38-55 minutes) to discuss potential attributes
and whether they perceived them to be meaningful. Additionally, we conducted
six cognitive interviews with review committee members that were on average 67
minutes (range 52-112 minutes) and iterated on three versions of the survey that
included about 50 detailed wording iterations. Details of committee membership
and interactions are outlined in Table 3.1.




Stakeholders were critical in helping to make ethical choices about study inclusion
criteria. The scientific team aimed to balance an obligation to allow as many par-
ticipants as possible with concerns about potential negative psychological impacts
of participation. We originally intended to include caregivers of children age 5 and
above. Stakeholders contributed to an improved understanding of the psychologi-
cal impact of the experiment. After a review committee participant with a young
child experienced emotional upset during the survey, the committees explored the
implications of a survey about pulmonary decline, which is a later-onset manifesta-
tion of DBMD, for parents of young children. This led to further consideration of
participant protection and the potential for scenario rejection, resulting in changing
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the inclusion criteria for parents to those whose child was at least 10 years of age.
Similarly, based on feedback from the adult stakeholders with DMD, we raised the
minimum age for teenage participation from 10 to 14 years.
Survey design
Consistent with best practices, the scientific team did not finalize the survey design
until after the community considered the attributes. The research team originally
proposed a DCE to measure treatment preferences for benefits and risks, but as it
became clear that the survey would include two attributes related to pulmonary
outcomes, the scientific team felt that a BWS case 2, which focuses on choices
among attributes within a profile, would be more productive than DCE, which fo-
cuses on choices among profiles. This allowed for greater differentiation between the
two pulmonary attributes. Similarly, the experimental design originally included
six attributes with three levels each. Engagement efforts elucidated that there were
two core, meaningful benefit attributes that reflected but did not significantly over-
state the potential benefits of the drug. Engagement also reinforced stakeholders’
overall desire to reduce complexity. Thus, to minimize respondent burden and in
the interest of facilitating the participation of teenage respondents, an abbreviated
version of the BWS case 2 experiment included only four attributes (cough strength,
chance of lung infections, chance for diarrhea and need for additional blood tests).
Finally, stakeholders reinforced the importance of incorporating an “intention to
use” question for each treatment profile, similar to an approach previously used by
our group [36].
Based on a desire to maximize the impact of the study on the entire drug
development process, the final survey also included an exploratory BWS case 1
experiment of 11 attributes (five per task) to measure respondent’s priorities for
non-skeletal muscle DBMD signs and symptoms as treatment targets. Stakeholders
selected weaker ability to cough, lung infections, weaker heart pumping, frequent
waking at night, bone fractures, constipation, headaches, feeling tired, non-healthy
weight, poor attention span and depression. These objects and definitions are
shown in Table 3.2. As previously described, these items emerged from the leader-
ship and stakeholder committee processes. Based primarily upon request from the
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sponsor and with support from the leadership committee, a third section compris-
ing a series of six Likert-type questions was added to describe additional benefit
and burden variables of interest. The final version of the attributes and levels used
in the survey can be found in Table 3.3.
Table 3.2: Refined objects and definitions for BWS case 1 experiment.
Attribute refinement
Community engagement was vital to informing the presentation of pulmonary ben-
efits, for two reasons. First, though pulmonary decline is ubiquitous as Duchenne
progresses and contributes substantially to morbidity and mortality, pulmonary
decline is asymptomatic or associated with diffuse symptoms for a significant por-
tion of affected individual’s lives, making the identification of meaningful attributes
more challenging [30-34]. As a result, clinician, patient and caregiver stakeholders
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Table 3.3: Refined attributes and levels for BWS case 2 experiment.
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agreed that most patients view lung function as important but may feel limited im-
mediacy for this outcome, especially at younger ages. Similarly, adults with DMD
had difficulty conceptualizing how a pulmonary benefit might affect their activities
of daily living. Thus, though all agreed that pulmonary benefits would be seen as
important, they acknowledged the hidden nature of pulmonary benefits and agreed
that the attributes would be more meaningful if tied to “visible” outcomes of pul-
monary function. Pulmonary benefits of interest were potential patient-relevant
downstream benefits such as daytime fatigue, sleep quality, headaches, and mor-
tality; clinician and advocacy advisors, however, cautioned that they would not
describe such benefits to their patients without additional data on the therapeutic
effects. This reflects the inherent tension between the pulmonary benefit used in
the clinical trial (upon which the study was based) and the benefits important to
patients and families. To achieve our goals, it was vital that we developed mean-
ingful attributes that were as consistent with the trial benefits as possible, while
remaining understandable and accessible to those in the DBMD community.
Thus, our engagement process determined that the survey would not include
a global pulmonary attribute or a functional measurement such as peak expiatory
flow (PEF) or forced vital capacity (FVC), which were the clinical trial outcomes.
Though not primary endpoints, the clinical trial did measure number of respiratory
infections and cough strength. These were considered to be meaningful to our
stakeholders, even for patients and parents who could not yet clearly anticipate
how such benefits would impact their day-to-day lives. Frequency of lung infections
and slowing the decline of cough strength were the benefits ultimately used in the
survey. The specific wording of the attribute levels and the instruction set were
also developed in collaboration with our stakeholder groups.
3.5 Discussion
We present a community engagement process and demonstrate its use for stated-
preference survey design. We offer a pragmatic, cost and time-permissive engage-
ment process to guide attribute development that is not in conflict with the qual-
itative research employed by other researchers in choice survey development [17,
37-38]. Using the classification system used to evaluate community engagement
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strategies in Clinical and Translational Science Award (CTSA) program applica-
tions [39], our process meets the criteria for designation as “high-input” from the
community. Furthermore, our process has similarities with the FDA’s process for
developing patient-reported outcomes (PRO) measures [40]. Both processes are
iterative, focus on content validity, and begin with conceptual development by a
scientific team and use patient input to adjust and refine [40].
A key element to understanding the community, its constituents and its capa-
bilities was the collaboration between research and advocacy organizations. The
study was co-led by advocacy and academic institutions, with support from the trial
sponsor. The collaborative scientific team included experts in the use of stated pref-
erences at Johns Hopkins University and PPMD, a team that has demonstrated
leadership and influence in the movement towards PCBR assessment in regulatory
decision-making and community-engagement expertise [29,4]. PPMD is also an
organization working solely to advance the needs of the DBMD community and
therefore its team members have condition-specific knowledge and a deep under-
standing of their community [35]. The scientific team previously conducted engage-
ment together, which allowed these efforts to be viewed as part of an evolutionary
process and build off of previous efforts [4,29,36,41]. Partnerships with organiza-
tions less entrenched in the disorder community of interest, and/or with limited
engagement experience may require guidance about and more time to conduct this
process, which underscores the importance of this work as an exemplar.
A limitation of our engagement was that all committee members had DMD,
leaving BMD under-represented. However, these are related disorders with symp-
tomatic overlap, and our committee members represented diversity in symptomatol-
ogy and progression. Similarly, all of our caregivers were mothers. The absence of
fathers reflects the common bias of mothers as caregivers for children with pediatric
onset disorders and as participants and targets of caregiver research in Duchenne
[41-44]. The presence of fathers is not likely to alter the results because the goal of
engagement was not consensus regarding survey attributes for inclusion, but aimed
to optimize attribute presentation, which is not expected to differ for fathers. In-
terpretation differences would likely be confounded with caregiver-burden, in which
case factors other than sex are more influential such as parental experience, patient
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functional status, psychological outcomes, and coping styles [44-46]. We aimed to
engage a variety of parents in terms of influencing factors where appropriate.
A limitation of this approach is that, while the process is transferrable, the
specific engagement must be tailored to each stated-preference study. Due to the
time-intensive nature of these activities, it may be useful to conduct them con-
currently with other regulatory review preparations to avoid extending the drug
development timeline. The risk of repeated demands on the community is also of
concern, particularly for rare diseases with smaller communities. Repeated use of
the same motivated participants puts them at risk for burn out. This risk can
be reduced by ensuring engagement activities serve as a source of empowerment
for community-members by communicating the meaningful impact on research and
enabling considerations of real-life decision-making scenarios they might face in the
future [35].
Engagement activities led to concrete changes to the study, such as a re-
evaluation of the overall experimental design, both in terms of the type of choice
tasks and the number of attributes. Therefore, it is important that engagement
be conducted in iterative, cyclical stages rather than consecutive stages to best
inform the survey design. This is consistent with the key principles of other en-
gagement frameworks [47]. Using information gained from engagement, we opted
for a BWS design, despite the fact that DCE has the advantage of having the
ability to calculate maximum acceptable risk.
In this example, the scientific team had a clear directive to determine how the
community views the benefits and risks associated with a potential pulmonary ther-
apeutic and we worked to engage the community within those parameters. This
necessitated that one attribute be related to pulmonary benefit and the other bene-
fits and risks to be of similar range for the experiment to be able to meet the study
goals. Engagement helped to define other tangible benefits that were considered to
be meaningful on a similar scale. The underlying assumptions of choice methods
require that no attribute dominate the others so that there are observable trade-offs
[48]. For instance, including a significant skeletal muscle benefit may have caused
the experiment to fail because it would likely have dominated the other potential
benefits.
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Trial sponsors and the FDA operate within a research culture that shapes their
beliefs and understanding of health and illness in terms of measurable clinical end-
points. An essential part of community engagement is to strive to understand
the patient’s point of view and how it shapes understanding of health and illness
[35]. For instance, engagement highlighted that the natural history of the disease
is such that many people do not experience obvious respiratory symptoms until
later stages of disease and therefore the community felt disconnected from the clin-
ical trial endpoint. Engagement prevented imposing a research cultural context
onto the community, which ultimately improves the research impact by ensuring
relevancy and expediting translation into practice.
The gains from engagement can apply to the broader drug development land-
scape as well. For instance, our BWS case 1 experiment asks respondents to pri-
oritize the aspects of the disease they would most prefer drugs to address. This
information can be used by sponsors developing the next generation of therapies,
or by priority-setting funding agencies. This information would also be useful to
determine relevant patient-centered outcomes as secondary clinical trial endpoints.
Furthermore, quantifiable risk tolerance information such as that provided in our
BWS case 2 experiment may also inform future research directions rather than
relying on assumptions about what level of risk patients and caregivers are willing
to accept.
3.6 Conclusions
This study describes a process for developing a stated-preference survey for patient-
centered benefit-risk assessment within the context of an existing therapeutic agent
after clinical trial. We demonstrate that a community-engaged approach can in-
corporate community members as varied as adult patients, caregivers, clinicians,
clinical trial sponsors, and professional advocates who can contribute important
information to the survey design. We established that community engagement en-
hances the process of attribute refinement for patient-centered drug development,
a context in which the goal is to understand patient priorities and preferences.
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4.1 Abstract
Background Patient preferences are increasingly considered important for regu-
latory decision-making, but less attention has been given to their use in earlier
stages of drug development or for building a body of preference knowledge. The
primary objective of this study was to quantify patient and caregiver priorities for
therapeutic targets in Duchenne and Becker muscular dystrophy. The secondary
objective was to explore heterogeneity.
Methods This study utilizes a best-worst scaling case 1 experiment to elicit treat-
ment priorities for 11 symptoms. Priority scores were calculated using conditional
logistic regression for the aggregate sample and stratified by caregivers and pa-
tients. A two-class latent class analysis identified segments of the sample with
differing preferences.
Results Results indicate that respondents in aggregate prioritize “weaker heart
pumping” (score = 4.67; 95%CI = [4.22, 5.12]) and pulmonary symptoms: ”lung
infections” (score = 3.82; 95%CI = [3.39, 4.24]) and “weaker ability to cough”
(score = 3.45; 95%CI = [3.05, 3.85]) as the most important intervention tar-
gets and ”poor attention span” as the least important intervention target (omit-
ted category). There were no significant differences between caregivers and pa-
tients (p − value = 0.14), but at least two classes exist with different priori-
ties. Priorities of the majority class (80%) are reflective of the aggregate results,
whereas the minority class (20%) considers “weaker heart pumping” (score =
2.84; 95%CI = [2.35, 3.33]) as more important than “weaker ability to cough”
(score = 1.67; 95%CI = [1.11, 2.23]) and “lung infections” (score = 1.58; 95%CI =
[1.06, 2.09]). Minority class membership was associated with ambulation (OR =
6.166, SE = 5.23) and inversely associated with use of cough assistive devices
(OR = 0.027;SE = 0.03), indicating less advanced disease.
Conclusions Estimates of the relative importance for therapeutic targets for Duchenne
muscular dystrophy indicate that symptoms related to quality-of-life and with di-
rect links to morbidity and mortality are prioritized above other quality-of-life
measures. Findings also suggest the existence of preference heterogeneity for treat-
ment targets, which may be related to symptom experience.
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4.2 Background
The muscular dystrophies (MD) are a group of muscle diseases characterized by
progressive muscle loss and shortened lifespan [1]. Duchenne muscular dystrophy
(DMD) is the most common and most severe form. DMD is a rare, genetic disease
occurring in 1 in 5,000 live male births [2,3]. The average age of diagnosis is five
years old, although boys usually begin to exhibit signs and symptoms in their
toddler years when they begin to walk [4,5]. Loss of ambulation usually occurs
in the early teen years. In addition to orthopedic symptoms, muscle loss leads
to respiratory and cardiovascular complications. Cardiomyopathy and respiratory
complications are the leading causes of death, which on average occurs at age 30 [4].
Becker muscular dystrophy (BMD) has similar characteristics to DMD, but is often
milder and with slower progression [1]. There are currently no approved treatments
for Duchenne and Becker muscular dystrophy (DBMD) and the standard of care
relies on the off-label use of corticosteroids that have been shown to delay loss of
muscle and delay complications [4].
Recognizing that science may be years from a drug that targets the underlying
genetic defect for Duchenne and Becker muscular dystrophy (DBMD), the neuro-
muscular community is supportive of concurrent drug development efforts that aim
to preserve quality-of-life for those with DBMD [6]. The current drug development
pipeline includes drugs that target signs and symptoms of DBMD including muscle
strength and function and cough strength. Previous research demonstrates care-
giver preference for progressive loss of muscle function, a major quality-of-life issue,
over life-extending interventions [7,8]. It is unknown which other signs and symp-
toms of DBMD that reduce quality-of-life are desirable targets for intervention.
Drug discovery programs are often initiated due to lack of available treatment
options. Initial research includes developing a hypothesis for how a hypothetical
therapy can alter a disease pathway and a target is selected [9]. Other factors
for consideration in choosing targets include commercialization, profitability, and
potential for discoveries to have spillover effects for other diseases. There is little
evidence of substantial effort to adequately account for patient preferences when
identifying therapeutic targets. Awareness regarding the importance of quanti-
tative patient preferences in other aspects of drug development has increased in
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recent years. The FDA has developed guidance documents for industry on how
to incorporate these data into regulatory submissions [10,11]. The focus to date
on quantitative preference data has primarily been with regard to the regulatory
review process, and earlier stages of development are absent from the discussion [12-
15]. One exception comes from the Medical Device Innovation Consortium (MDIC),
a public-private partnership aimed at advancing regulatory science around the de-
velopment and approval of medical devices. This group has developed a framework
for incorporating patient preference information into the regulatory process [16].
As part of this framework MDIC identified opportunities for patient preference
information to be collected and incorporated throughout the entire drug develop-
ment lifecycle, such as building a body of patient preference knowledge that can
be collected throughout the product lifecycle and contribute to regulatory review
and post-market surveillance [16]. Specifically in the discovery and ideation phase,
stakeholder input is relevant to understanding the areas of opportunity for ther-
apy and pathways to addressing them.[16] Historically, this has relied heavily on
qualitative data that has limited ability to reflect a variety of perspectives. Quan-
titative preference elicitation methods on the other hand can identify heterogeneity
and there is a rapidly growing literature of examples of this in healthcare [17-30].
Quantitative data can be useful in framing benefit-risk issues, defining subpopula-
tions and serving a role further down the line in developing clinical endpoints for
trials.
Using DBMD as an example, this study demonstrates an empirical approach
to building a body of knowledge of quantitative preference information that can be
used in early phases of drug development and can assess preference heterogeneity
among patients with the same disease. The primary objective of this study was
to directly elicit patient and caregiver priorities for therapeutic targets for the
signs and symptoms of Duchenne and Becker muscular dystrophy. The secondary




This survey was developed using a community-engaged research approach so that
patients and caregivers, as well as other key stakeholders, informed the survey
design. Twenty stakeholders were involved in defining eligibility criteria, refining
attributes, and determining overall relevancy. This ensured that the survey and
list of attributes were meaningful to the community. In-depth details about the
community-engaged approach are available elsewhere (see Chapter 3).
Survey methods
Best-worst scaling (BWS) is a choice-based preference elicitation method used to
elicit preferences for various objects or attributes. Introduced in 1992 and with its
formal theoretical and statistical properties proven in 2005, it has become increas-
ingly popular in healthcare as an alternative to rating scales [31-34]. BWS is a
form of conjoint analysis that presents survey respondents with a set of items from
which the respondent identified the best and worst. There are three cases of BWS:
the object case (case 1), the profile case (case 2), and the multi-profile case (case
3). In case 1, the respondent chooses the best and worst objects among a list of
objects. In case 2, the respondent chooses the best and worst attributes and various
levels of that attribute from among a hypothetical profile. Finally, in case 3, re-
spondents choose the best and worst profiles from among a set of multiple profiles.
Complete theoretical explanations and examples of healthcare applications for all
three cases are available elsewhere [35,36]. In all three cases, the choices resulting
from consideration of multiple questions are analyzed together to estimate relative
importance.
Survey design
The final survey included a BWS case 1 experiment. This is an appropriate design
for determining the relative value of a list of objects [36]. In this study, there were
11 objects defined as signs and symptoms of DBMD that are potential targets of
therapeutic interventions. The list of objects were: weaker ability to cough, lung
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infections, weaker heart pumping, frequent waking at night, bone fractures, con-
stipation, headaches, feeling tired, non-healthy weight, poor attention span and
depression. Additional details about the definition for each object are described
in Table 4.1. Choice tasks were precipitated by a series of demographic questions
about the survey respondent, questions about the clinical status of the individual
affected with DBMD, and an introductory section that provided a brief definition
of each sign or symptom and then answered a question about their own experience
with that sign or symptom. For instance, after a brief definition of “lung infections”
caregiver respondents were asked “Has your child with DBMD ever been treated
for pneumonia” These salience questions were intended to pace the respondent’s
reading of the material and ensure the information was absorbed. It also provided
data for exploring the relationship between experiences with symptoms and prefer-
ences to target those symptoms. Respondents were also presented with an example
choice task to familiarize themselves with the experiment.
The objects were presented in 11 different choice tasks that each presented
a sub-set of five objects. An example choice task is presented in Figure 4.1. A
balanced-incomplete experimental design was used so that each object occurred
the same number of times and co-occurred with other attributes equally. The
design also had Youden design properties, which ensures that every object appeared
in the same position the same number of times (once) [37,38]. This prevents the
respondent from attributing importance to objects based on the composition of the
choice task [36]. Respondents were asked to evaluate the five objects and choose
the object that he or she considered the most important to treat and the object
that he or she considered the least important to treat. The design was identified
from the SAS database of orthogonal arrays [39]. The survey was administered
online using Qualtrics.
Figure 4.1: Sample BWS task used to elicit relative preferences for signs and symp-
toms as therapeutic targets.
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The intended respondents were patients with Duchenne or Becker muscular dys-
trophy and caregivers of children with DBMD. A targeted recruitment strategy
was used with the opportunity for supplemental snowball sampling. Potential re-
spondents were recruited via flyers at an annual patient and family conference in
June 2015. Two days following the conference, Parent Project Muscular Dystro-
phy (PPMD) sent emails to its DuchenneConnect registry participants who met the
survey eligibility criteria. A follow-up email was sent to the same distribution list
approximately one month later. Due to the difficulty in recruiting sufficient respon-
dents in a rare disease community, the survey link was public, which afforded the
opportunity for community members to invite other interested community members
to participate. The survey was in the field for 5 weeks.
The inclusion criteria for caregiver survey respondents were that caregivers had
to be at least 18 years of age and have at least one child with DBMD at least 10
years old. For patient respondents, the inclusion criteria were that he had to be
living with Duchenne or Becker muscular dystrophy and at least 14 years of age.
Only those living in the United States were eligible. The protocol for the study was
approved by the Institutional Review Board of Johns Hopkins Bloomberg School
of Public Health, Baltimore, MD (IRB # 00006299). All participants provided
informed consent electronically.
Statistical analysis
Choice outcomes across all 11 tasks were used to estimate the relative values asso-
ciated with objects. Responses were analyzed using sequential best-worst scaling.
Conditional logistic regression models produced estimates for the aggregate sam-
ple. The dependent variable was the choice of an attribute as best or worst. The
independent variables were 10 of the 11 available attributes. The attribute most
often chosen as least important was used as the reference category. The estimates
for the other 10 objects can be interpreted relative to the least important object.
The survey did not allow a respondent to advance to the next choice task without
answering the current task, therefore there were no missing data for the experi-
ment. The data were analyzed using STATA 14 (StataCorp LP, College Station,
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Texas).
Two secondary analyses were used to explore heterogeneity. First conditional
logistic regression models were repeated for stratified samples of caregivers and
patients. Overall models and individuals parameter estimates were compared us-
ing Wald tests. Second, we conducted a latent class analysis to explore potential
sources of heterogeneity. The results of this analysis include each respondent’s
probability of class membership and class-specific parameter estimates. Classes
were compared on the basis of demographic and clinical characteristics using t-
tests for independent samples. The results of comparisons were used to construct
a multivariate model with relevant covariates. Finally, logistic regression was used
to identify associations between demographic and/or clinical characteristics and
class membership. The outcome variable was minority class membership and the
independent variables were diagnosis, ambulatory status, respondent type, income,
and all of the 11 clinical characteristics associated with the signs and symptoms
from the experiment (listed in Table 4.1).
4.4 Results
Study sample
The survey link was distributed on June 20, 2015. Of 323 recipients who opened
the email invitation to participate, 93 clicked on the survey link (response rate:
29%). Additional people gained access to the survey through the aforementioned
snowball strategy. The survey was closed on July 30, 2015 at which point the
survey had been accessed 235 unique times. In 198 of those cases, the respondent
met the inclusion criteria and provided informed consent (consent rate: 83%). The
final sample of those who completed the BWS case 1 experiment included 155
participants (completion rate: 78%). Of the 43 that dropped out, most did so at
the start of the experiment; 86% (n=37) did not answer the first choice task, 11%
dropped out before the second task, and one respondent completed all but the final
task. Information about non-responders is not available.
Table 4.2 summarizes the respondent characteristics. Of the 155 respondents,
62% were caregivers (n = 96) and 38% were patients (n = 59). The majority of
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caregivers were 45 years or older (56%), which skewed the age distribution for the
aggregate sample. Patient respondents were 22% under age 18, 49% 18-30 years,
and 27% were over 30 years old. The majority of respondents were white (89%),
with 8% Hispanic and 5% black. The majority of respondents reported annual
household income greater than $50,000 (61%), and 19% that reported incomes
greater than $100,000). Respondents were disproportionately located in the South
(39%) and West (25%). The majority of caregiver respondents were married or in
long-term relationships (73%), but only 15% of patient respondents were married.
Of the caregiver respondents, an overwhelming majority were mothers (76%) and
highly educated (58% college graduates).
Table 4.2: Survey respondent demographic characteristics (n=155).
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As shown in Table 4.3, the majority of affected individuals had Duchenne mus-
cular dystrophy (85%), compared to 12% with Becker muscular dystrophy. Most
affected individuals had some history of steroid use (77% had used them previously
or currently) and a majority were non-ambulatory (63%), which was defined as
being able to do some walking indoors, even if they need help to do so and required
a wheelchair outdoors. Most respondents had either private health insurance cov-
erage (43%) or a combination of private and public plans (37%). Reflective of
the differences in eligibility criteria between caregivers and patients, and because
there were more caregiver respondents than patient respondents, the age distri-
bution for affected individuals age skewed young with 86% being 10-17 years old.
The mean age of affected individuals among patient respondents was 27.5 years
old (SD = 14.1). Additional details about experience with DBMD symptoms are
available in Table 4.3.
Statistical results
Priority scores
Figure 4.2 compares the relative importance of the 11 potential therapeutic targets
for the aggregate sample. The horizontal bars around each point estimate represent
the 95% confidence interval (CI) of that estimate. The most important symptom to
target was “weaker heart pumping” (score = 4.67; 95%CI = [4.22, 5.12]), followed
by “lung infections” (score = 3.82; 95%CI = [3.39, 4.24]) and “weaker ability to
cough” (score = 3.45; 95%CI = [3.05, 3.85]). The confidence intervals for “weaker
heart pumping” and “lung infections” overlap, but just barely, which indicates
that respondents did not differentiate cardiac targets from pulmonary targets. The
confidence intervals of the two pulmonary benefits (“lung infections” and “weaker
ability to cough”) overlap, indicating that respondents did not differentiate priori-
ties between these two targets. All three of the most important targets do not have
overlapping confidence intervals with any of the lower-ranked targets, indicating a
strong prioritization for cardiac and pulmonary targets. The least important target
was “poor attention span” and was used as the reference (omitted) object such that
all other estimates can be viewed as relative to it. None of the confidence intervals
for any of the targets overlap include zero, indicating that “poor attention span”
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Table 4.3: Clinical characteristics and symptom experience of individuals affected
with DBMD (n=155).
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is significantly different from the other targets.
Figure 4.2: Caregiver and patient aggregate relative priorities for therapeutic tar-
gets.
The next most prioritized symptom was “bone fractures” (score = 2.42, 95%CI =
[2.04, 2.78]), although it overlapped with “non-healthy weight” (score = 1.78; 95%CI =
[1.44, 2.22]). The differences in relative importance for many of the middle-importance
attributes were not statistically significant. The relative importance of “non-
healthy weight”, “depression”, “headaches”, and “constipation” were not distin-
guishable from one another based on overlapping confidence intervals. Although
non-healthy weight and depression were barely overlapping with “constipation”:
“non-healthy weight” (score = 1.78; 95%CI = [1.44, 2.22]) and “depression” (score =
1.74; 95%CI = [1.49, 1.99]) vs. “constipation” (score = 1.20; 95%CI[0.88, 1.52]).
The relative importance of “headaches”, “constipation”, “frequent waking at night”
and “feeling tired” were not significantly different.
Priority heterogeneity
A test between the caregiver and patient models indicates the overall models are not
significantly different from one another (p−value = 0.14). (Data not shown). Fur-
thermore, tests for differences between caregivers and patients for each individual
attribute were not significant (p−values > 0.05). The priority scores for depression
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were initially significantly different at the alpha = 0.05 level (1.99 for caregivers vs.
1.61 for patients; p− value = 0.02). However, once the Bonferroni correction was
applied to account for multiple comparisons, the result was no longer significant.
The relative preference order based on point estimates for some of the middle-
ranked items differed between caregivers and patients. For caregivers depression
was more important than non-healthy weight, whereas for patients the priority
order of these two targets was reversed. Similarly, for caregivers headaches were
more important than constipation, whereas for patients constipation was more im-
portant than headaches. However, overlapping confidence intervals between these
attributes indicates no true differentiation within these groups of objects.
A latent class analysis was conducted to explore other potential sources of
heterogeneity. Models for two classes up through 11 classes were evaluated for
minimum AIC and BIC values to determine the optimal number of classes for the
best-fitting model. However, model selection criteria were ultimately disregarded
in favor of a 2-class model due to the small sample size [40]. For the 2-class model,
80% of respondents make up the majority class and 20% of the respondents make
up a minority class.
As shown in Figure 4.3, the majority class reflected patterns similar to aggregate
results and demonstrated greater prioritization for the three signs and symptoms
that were prioritized in the aggregate analysis (cardiac and pulmonary symptoms).
Like the aggregate results, the overlapping confidence intervals indicate no differ-
entiation between “weaker heart pumping” (score = 5.87; 95%CI = [5.32, 6.42])
and “lung infections” (score = 5.08; 95%CI = [4.53, 5.61]) or “weaker ability to
cough” (score = 4.52; 95%CI = [4.07, 4.97]). For the minority class, “weaker heart
pumping” (score = 2.84; 95%CI = [2.35, 3.33]) was significantly different from the
both pulmonary measures: “weaker ability to cough” (score = 1.67; 95%CI =
[1.11, 2.23]) and “lung infections” (score = 1.58; 95%CI = [1.06, 2.09]). One dif-
ference between classes is that the minority class considered the two pulmonary
benefits to be indistinguishable from “bone fractures”, “feeling tired”, “depression”
and “non-healthy weight”. Furthermore, “lung infections” was also indistinguish-
able from “headaches” in the minority class. Like the aggregate results, many of
the middle attributes were not statistically significantly different from one another
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within classes. One exception was that the minority class prioritized “feeling tired”
(score = 1.91; 95%CI = [1.34, 2.48]) above “frequent waking at night” (score =
0.47; 95%CI = [0.03, 0.91]) and “headaches” (score = 0.64; 95%CI = [0.19, 1.09]).
Figure 4.3: Caregiver and patient segmented (2-class) relative priorities for thera-
peutic targets.
Respondent type (caregivers and patients) was significantly different between
classes, but did not perfectly predict class membership. Caregivers and patients
made up 66% and 34% of the majority class, respectively and 45% and 55% of the
minority class. Comparing the demographic and clinic characteristics of each class,
we found no significant differences in diagnosis and ambulatory status between
classes. In the majority class, a larger proportion of the affected individuals had
Duchenne and a smaller proportion had Becker compared to the minority class (89%
Duchenne and 10% Becker in majority class vs. 71% Duchenne and 19% Becker
in minority class; p − value = 0.04). Ambulatory status also differed between
classes. A much larger proportion (58%) of minority class respondents identified
as ambulatory compared to majority class respondents (58% vs. 31%; p− value =
0.01).
The results of the logistic regression examining the association between demo-
graphic and clinical characteristics with minority class membership are presented
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in Table 4.4. Minority class membership is associated with being ambulatory com-
pared to non-ambulatory (OR = 6.16; p− value = 0.03), history of bone fractures
compared to no history of bone fracture (OR = 4.83; p − value = 0.04), and
occasional trouble sleeping compared to never or rarely having trouble sleeping
(OR = 13.79; p − value = 0.03). Minority class membership is inversely asso-
ciated with using cough assistive devices compared to not having used a device
(OR = 0.027; p − value = 0.01), and frequent trouble concentrating compared to
never or rarely having trouble concentrating (OR = 0.031; p− value = 0.03).
4.5 Discussion
In this study, we estimated the relative importance for therapeutic targets for
Duchenne muscular dystrophy. Because there was little distinction between at-
tributes among the top 3 attributes or between attributes of middle-level impor-
tance, results are best ordered according to four groups. Among an aggregate sam-
ple, cardiac (“weaker heart pumping”) and pulmonary benefits (“lung infections”
and “weaker ability to cough”) were the most highly prioritized targets. “Bone
fractures”, “non-healthy weight” and “depression” were second most prioritized.
The third group includes “headaches”, “constipation”, “frequent waking at night”
and “feeling tired”. All of above are desired targets of intervention more than
“poor attention span”. However, it warrants emphasizing that these are relative
importance weights, and therefore none should be viewed as unimportant.
When two classes are distinguished, the minority class, although prioritizing
cardiac symptoms above all else, considered pulmonary benefits to be undifferenti-
ated from “bone fractures”, “feeling tired”, “depression” and “non-healthy weight”.
Feeling tired was prioritized higher among the minority class, making it fall into
the second group, rather than the third.
Regression results comparing class membership and characteristics indicate a
higher prioritization for signs and symptoms as treatment targets for which there is
more experience with that target. “Bone fracture” was attributed greater relative
importance in the minority group, a group in which those with history of bone
fracture had 5 times greater odds of minority class membership. On the other
hand, the minority class attributed less relative importance to pulmonary benefit;
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Table 4.4: Logistic regression results for probability of minority class (20%) mem-
bership.
51
ambulatory respondents had 6 times greater odds of minority class membership.
Similarly, those having used cough assistive devices had lower odds of minority class
membership. This may indicate that the minority class has less advanced disease
and that lack of experience with pulmonary symptoms may make it a less desirable
treatment target. This result is consistent with qualitative community-engagement
work we did in the survey development phase in which caregivers and patients had
trouble relating to downstream pulmonary benefits which aren’t experienced until
later stages of disease progression (see Chapter 3).
Because these two models are estimated separately, and because this study
discusses averages and not individuals, conclusive statements can not be made with
regards to influential factors on individual-level preferences for treatment targets.
However, we can conclude that preference heterogeneity does exist and should be
accounted for in future research and needs assessment. This study indicates that
preference heterogeneity may be particularly important among treatment targets
related to quality-of-life. The most important target (“weaker heart pumping”),
although also quality-of-life related, has an apparent, well-known link to morbidity
and mortality. Therefore its prominence may be the reason there is consensus
regarding its relative importance. Whereas, the targets of middle-priority are also
related to quality-of-life, but lack as clear of a link to morbidity and mortality as the
cardiac symptoms and may be influenced to a greater degree by past experience or
current health status. Drug developers in needs assessment phases should consider
quality-of-life targets.
A limitation of this work is that progressive loss of muscle function, the key-
stone characteristic of DBMD is not included in the list of potential treatment
targets. Stopping and slowing the progressive loss of muscle has been shown to be
very important to caregivers; results of a previous study of benefit-risk tradeoffs
demonstrated a strong preference for slowing the progression of muscle weakness,
even in the presence of a serious risk.[7] It was not included because this survey
was developed in response to FDA guidance so that the data could be used as part
of a regulatory review process for a drug with demonstrated pulmonary benefits in
phase III clinical trials. As such, we were particularly interested in understanding
preferences for pulmonary benefits.
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4.6 Conclusions
We estimated the relative importance for therapeutic targets for Duchenne mus-
cular dystrophy. Understanding the preferences of caregivers and patients has
implications for drug development and regulatory decision-making. In summary,
we found that on average respondents identified cardiac and pulmonary symp-
toms as the most important symptom to target with no differentiation between
the two. Although we did not find differences between caregivers and patients, we
did find that there are at least 2 classes of respondents with different priorities.
The majority class considers pulmonary symptoms to be as equally important of
a therapeutic target as cardiac symptoms, whereas the minority cluster considers
is to be less important. This may be due to lack of experience with a symptom or
less advanced disease progression. Further research is needed to better understand
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5.1 Abstract
Background Incorporating patient preferences into regulatory decision-making in
a scientific manner is particularly important for rare diseases with high degrees
of uncertainty and in which reviewers have limited clinical experience. In direct
response to guidance, a stated-preference study was conducted to measure patient
preferences information for regulatory review of a therapeutic agent for Duchenne
muscular dystrophy (DMD) that demonstrated pulmonary benefits in a phase III
clinical trial. This paper quantifies patient and caregiver preferences for a therapeu-
tic agent for DMD, a progressive neuromuscular disorder with expected pulmonary
decline. We also explored differences in caregiver and patient preferences.
Methods A best-worst scaling case 2 survey with nine profiles was administered to
133 caregivers and patients with DBMD. Respondents selected the best and worst
attributes from among 4 attributes at 3 levels. Utility scores were estimated using
mixed logistic regression.
Results Respondents demonstrated greatest preference for therapies that maintain
their current level of cough strength for 10 years (score = 3.893;SE = 0.09) or
for 2 years (score = 3.027;SE = 0.09). Preference scores for risks were low; 50%
chance of diarrhea (score = −1.943;SE = 0.08) and 4 additional blood draws per
year (score = −1.883;SE = 0.08).
Conclusion Results demonstrate a strong preference for pulmonary benefit and
willingness to trade-off risks and burden to achieve these benefits. In exchange
for maintaining cough strength for 10 years, respondents were willing to tolerate
high probabilities of diarrhea and additional blood draws. Although not powered
to detect statistically significant differences, there were no qualitative differences
in preferences between caregivers and patients.
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5.2 Background
Regulatory decision-makers often lack reliable information to make data-driven
patient-centered benefit-risk assessments. In an effort to rectify this, Congress
mandated regulatory decision-makers incorporate patient preference information
into benefit-risk assessment [1-2]. Patient-centered benefit-risk (PCBR) assessment
is an increasingly-favored approach of doing this in a vigorous way [3]. Historically,
the Food and Drug Administration (FDA) has relied on patient testimony for
patient preference information. Although powerful, these anecdotes are biased,
limited in their representation of diverse viewpoints, and fail to provide quantitative
data about minimal benefit and acceptable risks.
The FDA has become increasingly interested in PCBR because of its ability to
provide information about factors that patients and families will tradeoff in making
decisions to use new technologies, including quantifying risk tolerance and mini-
mum required benefit. The FDA has encouraged its reviewers to consider patients’
perspectives when such information is available, and has participated in its own
patient-preference study [4-5]. FDA staff have published editorials in scientific jour-
nals and the agency published guidance for drug developers, or sponsors, regarding
what, how and when patient preference data may be considered during the review
process [6-7]. As part of a public/private partnership, they have also been part
of a consortium that developed a framework for incorporating patient preference
information into regulatory assessments of new technologies [8]. The FDA has also
highlighted the importance of this data for preference-sensitive decisions in which
there is significant uncertainty and/or patients’ views may differ considerably from
those of researchers and clinicians [8].
Rare diseases provide a preference-sensitive context that is particularly well
suited for incorporating patient preference information due to high unmet need,
shortened lifespan, limited treatment options, and high degrees of uncertainty [7-
8]. Furthermore, reviewers may have limited clinical or personal experience with a
rare condition, increasing the likelihood that patient preferences differ from those
of reviewers and clinicians [7-8].
Recognizing the relevancy for its patient population, Parent Project Muscu-
lar Dystrophy, an advocacy organization focused on finding a cure for Duchenne
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muscular dystrophy (DMD), developed draft guidance for industry that calls for
incorporating patient preferences [9-10]. The FDA followed with its own draft
guidance for industry developing drugs for DMD that acknowledges patient and
caregiver benefit-risk tolerance and preference heterogeneity should be considered
in regulatory decisions [11]. DMD is a serious neuromuscular disorder of pediatric
onset. It causes progressive muscle weakness with respiratory failure as the leading
cause of death [12-16].
Despite significant progress in developing a framework and proposing processes
for incorporating patient preferences in regulatory decision-making, it is still a
nascent field with few examples of formal consideration of patient preference infor-
mation in benefit-risk assessment for new drug therapies. As such, there is little
understanding for how drug developers, or sponsors, will respond to the recent
guidance and increasing emphasis on patient preferences.
Patient preference studies have been previously used to quantify patient pref-
erences for hypothetical therapeutic options that would slow the progression of
muscle weakness [17]. To our knowledge, the following paper is the first preference
study to be developed in direct response to guidance for sponsors. The objective of
this paper is to quantify patient and caregiver preferences for a therapeutic agent
for DMD that demonstrated pulmonary benefits in a phase III clinical trial. The
decline of pulmonary function is progressive and results in considerable morbidity
and mortality typically following the loss of ambulation in the 2nd decade [12-16].
We hypothesize that caregivers and patients will be willing to trade moderate risk
for pulmonary benefits. A secondary objective is to explore caregiver and patient
preferences. We expect that caregivers and patients may have different preferences.
5.3 Methods
Survey development
A community-engaged approach was used to elicit feedback from key stakehold-
ers regarding attribute selection and refinement. A total of 20 stakeholders were
involved in over 15 hours of formal engagement over 4 months. The group was
organized across three committees (leadership, stakeholder and review committee)
60
and provided feedback at various time points to allow for an iterative design ap-
proach. Additional details about the community-engaged approach and the model
for survey development are published elsewhere (see Chapter 3).
The final survey included a best-worst scaling (BWS) case 2 (profile case) ex-
periment with four attributes with three levels each, one of which was a reference
level of no benefit or no risk. Benefits did not represent disease reversal, but rather
were operationalized to offer a slowing of disease progression. The benefits included
maintaining level of cough strength (maintain for 10 years, maintain for 2 years,
or no benefit) and reducing the frequency of lung infections (very few infections,
half as many, or no reduction). Risks included a common side effect to many
drug therapies operationalized as diarrhea (no risk, 20% risk, or 50% risk) and a
burden-related measure of blood monitoring frequency while on the treatment (no
additional blood draws, two additional blood draws per year, or four additional
blood draws per year).
Survey design
The computer-based survey was programmed and administered in Qualtrics. The
survey was self-administered and included demographic questions about the re-
spondent and clinical questions about the affected individual such as ambulation
status, type of muscular dystrophy and history of steroid use. The survey con-
sisted of four stated-preference exercises, however only the results of the BWS case
2 (profile) experiment and a follow-up simple discrete choice task are reported here.
BWS is stated-preference method that has been developed more recently and con-
tinues to grow in popularity among healthcare applications [18-27]. In BWS case 2,
respondents evaluate one treatment profile at a time and provide two data points
per profile (best and worst) [28]. Across 9 choice tasks, respondents selected the
best and worst attributes from among 4 attributes at 3 varying levels. See Figure
5.1 for an example choice task. Respondents could not advance to the next task
without selecting both a best and worst choice, thereby forcing a choice.
After each treatment profile, respondents were asked about their intention to
use this treatment if it were available to them. Concordant use of BWS case
2 and a simple conjoint analysis experiment in a single survey has been shown
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Figure 5.1: Sample choice task for BWS case 2 (profile) experiment and follow-up
intention to use question.
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to be useful for patient preference research intended to inform regulatory decisions
making because the interpretation and application of the combination of data helps
to understand risk tolerance, meaningful benefits, and explore intention to use
specific therapies [29].
A 34 main effects orthogonal, fractional experimental design was used such that
the attribute levels presented for each attribute across tasks were balanced and un-
correlated. This design is accessible and focuses on statistical efficiency because the
minimum number of treatment profiles are used to ensure uncorrelated attributes
[26,30-31]. The design was identified from the SAS database of orthogonal arrays
[32].
Recruitment
Respondents were recruited through multiple sources targeted at qualifying respon-
dents between June 18, 2015 and July 30, 2015. Recruitment initiated at the PPMD
annual conference and was followed by targeted emails directed to DuchenneCon-
nect registry participants. Respondents were also recruited through a grass-roots
parent led outreach initiative of Parent Project Muscular Dystrophy (PPMD).
Eligibility criteria included living in the United States and being either the
caregiver of someone living with Duchenne or Becker muscular dystrophy or a
patient with the same condition. Caregivers had to be at least 18 years of age and
their affected child was required to be at least 10 years old. The minimum age for
patient respondents was 14 years. The protocol for this study was approved by the
Institutional Review Board of Johns Hopkins Bloomberg School of Public Health,
Baltimore, MD (IRB # 00006299). All participants provided informed consent
electronically. Teen participants participated with a guardian’s permission.
Analysis
Fischer’s exact tests were used to test for differences in relevant characteristics
of the affected individual with DBMD across caregiver and patient respondents.
Differences for characteristics of the survey respondents were not tested because
the groups are expected to be different.
The analysis assumes that the choice of the best and worst item represents the
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extreme ends of a latent ranking of item importance and therefore the utility scores
can be compared to represent the difference between the degree of importance
among items [33]. Utility scores were estimated using mixed logistic regression
with effects coding for the stratified samples (caregivers and patients) and the
pooled sample. The forced choice design allowed for a complete case analysis. For
the stratified analysis, caregiver and patient utility scores were compared using
t-tests at the 95% confidence levels and with Bonferroni adjustments for multiple
comparisons. Coefficients for the standard deviations of each attribute’s choice are
used to represent the degree of heterogeneity in an attribute. Using the aggregate
analysis of combined caregivers and patients, coefficients for the means for the
attribute/level combinations were rescaled such that the category representing no
change from baseline is anchored at zero. Probabilities of intentions to treat were
estimated by calculating the means for the respondents selecting that they would
use the treatment. We calculated relative attribute importance using best-minus-
worst scores by summing the number of times that an attribute was chosen as best
or worst, regardless of the level. We conducted exploratory analyses looking at
results stratified by respondent type (caregivers or patients). All analyses were
conducted using STATA 14 (StataCorp LP, College Station, Texas).
5.4 Results
Descriptive statistics
A total of 133 respondents completed the BWS case 2 experiment comprised of
61.7% caregivers (n = 82) and 38.3% patients with DBMD (n = 51). Table 5.1
provides a complete list of respondent characteristics. Caregiver respondents were
primarily biological mothers (77%, n = 63). Other caregiver types included biologi-
cal fathers (16%, n = 13), adoptive mothers (6%, n = 5) and grandmother acting as
a guardian (1%, n = 1). The majority of caregivers were married or in long-term re-
lationships (72%, n = 59). The mean age of participants was 46.8 years (SD=8) for
caregivers and 27.7 years (SD=14) for patients. The majority of respondents were
white (88%, n = 72) and living in higher income households with 86.5% (n = 71)
of caregivers and 47.2% (n = 25) living in households earning more than $50,000
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per year.
Table 5.1: Demographic characteristics of survey respondents.
As shown in Table 5.2, most affected individuals had a diagnosis of Duchenne
muscular dystrophy. Although this was lower among adult respondents (82%, n =
42) compared to caregiver respondents (88%, n = 72), this was not a statistically
significant difference. The majority of affected individuals had current or past his-
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tory of steroid use. Caregivers reported that 83% (n = 68) of their affected children
had current or past history of steroid use and 69% (n = 35) of patients reported
current or past history of steroid use. The majority of affected individuals were
either privately insured (caregivers : 46%, n = 38; patients : 39%, n = 20) or pri-
vately insured and received public insurance (caregivers : 34%, n = 28; patients :
45%, n = 23). Only mean age of the affected individual had a statistically sig-
nificant difference between the caregiver group (mean = 16.0, SD = 6) and the
patient group (mean = 27, SD = 14). This is expected given the eligibility criteria
for participation. There was also a wider range for the age of the patient group,
which is consistent with the larger proportion of respondents in that group with
Becker muscular dystrophy, which is associated with longer lifespan.
Table 5.2: Demographic and clinical characteristics of affected individuals.
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Utility scores
The results of mixed logit analyses for the stratified groups are shown in Table 5.3.
Respondents demonstrated the greatest preference for a therapeutic agent that
maintains their current level of cough strength for 10 years (caregivers : score =
1.697, 95%CI = [1.44, 1.95]; patients : score = 1.446, 95%CI = [1.19, 1.74]) and
for 2 years (caregivers : score = 0.716, 95%CI = [0.49, 0.94]; patients : score =
0.746, 95%CI = [0.44, 1.05]). Though respondents preferred half as many lung
infections (caregivers : score = 1.118, 95%CI = [0.90, 1.34]; patients : score =
0.907, 95%CI = [0.65, 1.16]) over very few lung infections (caregivers : score =
0.790, 95%CI = [0.52, 1.06]; patients : score = 0.870, 95%CI = [0.59, 1.15]),the
overlap in the confidence intervals between the two levels demonstrate no significant
difference in preferences.
Table 5.3: Mixed logit results for caregiver and patients preferences for benefits
and risks.
Respondents had the lowest preference for a therapeutic agent with no benefit to
cough strength (caregivers : score = −2.413, 95%CI = [−2.70,−2.13]; patients :
score = −2.212, 95%CI = [−2.54,−1.88]) followed by an agent with no benefit to
67
lung infections (caregivers : score = −1.908, 95%CI = [−2.21,−1.61]; patients :
score = −1.777, 95%CI = [−2.08,−1.47])-these were preferred less than even a
50% risk of diarrhea (caregivers : score = −0.884, 95%CI = [−1.08,−0.68]; patients :
score = −0.561, 95%CI = [−0.81,−0.31]).
As shown in Table 5.3, the differences in preference scores were not statisti-
cally significantly different across caregiver and patient groups. Furthermore, the
standard deviations of the preference scores are not statistically significant for 75%
of the attribute/level combinations (see Table 5.3). A p − value < 0.05 indicates
statistically significant heterogeneity. However, results indicate statistically signif-
icant heterogeneity only for cough strength maintained for 10 years, very few lung
infections, and no reduction in lung infections among caregivers and only for cough
strength maintained for 2 years among patients. Overall, comparing caregiver and
patient preferences for DBMD treatments showed no significant quantitative differ-
ences and no qualitative differences between the two groups. Therefore, to under-
stand attribute importance, minimal acceptable benefit and maximum acceptable
risk, pooled results are shown. See Figure 5.2.
Relative attribute importance revealed that respondents were most concerned
with a treatment’s ability to address benefits compared to a treatment’s risks. Re-
sults were similar across both groups and there were no statistically significant dif-
ferences between them. Cough strength had the greatest importance (38.3%), fol-
lowed by fewer lung infection (26.5%), diarrhea (18.6%) and blood draws (16.5%).
Intention to use treatments
As shown in Figure 5.3, for 8 of 9 profiles there was a more than 65% probability
that respondents intend to use the treatment. For four treatment profiles, there
was a probability greater than 80% of use. All of these profiles had a benefit of
maintaining cough strength for at least two years and three of four had a moderate
benefit for lung infections. For most treatment profiles there were no significant
differences between caregivers and patients, with one exception. Treatment profile
E had a 57% probability of take-up among patients and a 76% probability of take-
up among caregivers.
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Figure 5.2: Mixed logit results for aggregate preferences for benefits and risks.
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Figure 5.3: Probability representing intention to use treatment profile by respon-
dent type and corresponding treatment profiles.
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5.5 Discussion
Overall, caregivers and patients endorsed similar preferences for DBMD treatments.
Respondents demonstrated greatest preference for maintaining cough strength and
reducing the number of lung infections compared to the risk of diarrhea and ad-
ditional blood monitoring. The maximum risk that participants were willing to
accept was a 50% increased risk for diarrhea in addition to the burden of twice
yearly blood monitoring, in order to maintain their current level of cough strength
for up to 10 additional years. The maximum risk that participants were willing
to accept in order to maintain their cough strength for two years was 20% risk of
diarrhea and blood monitoring an additional two times per year.
Preference scores for “no benefit to cough strength” and “no benefit to lung
function” are the lowest, which demonstrates that respondents prefer some risk over
no benefit to cough strength or lung infections. This has important implications
for quantifying the patient and caregiver’s willingness to trade-off-information that
should be used to inform regulatory decision-makers for benefit-risk assessments.
These findings were supported by data resulting from the follow-up discrete
choice question, in which participants were asked about whether they intend to use
the treatment. A large majority of respondents were willing to try a treatment
that offers a moderate benefit even with the highest levels of risk and burden (see
profile E in Figure 5.3). This information is also important for regulators in terms
of understanding whether people are likely to use a therapy if approved.
For BWS experiments it is important that the attributes are independent of one
another. This is both for the statistical design properties and because respondents
may be confused by overlapping attributes if a profile seems to have contradictory
attribute levels. Although cough strength and lung infections are both related to
pulmonary function, the data exhibit no signs of serial non-attendance to any one
attribute, which indicates respondents differentiated between the two pulmonary
measures. Furthermore, there were no signs of universal acceptance indicating that
participants were actively making trade-offs.
Unexpectedly, the results for the lung infection attribute were not monotonic.
“Very few lung infections” was the level designed to represent the greatest improve-
ment in frequency of lung infection; however, respondents chose it as worst more
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often than they chose “about half as many lung infections” as worst, which was
designed to be the middle level of benefit. Respondents had an educational por-
tion prior to the choice tasks in which they were provided with assumptions about
the attribute and level definitions, because ”very few” is not quantifiable whereas
”half as many” is quantifiable, the ordinal nature of the levels may not have been
obvious within a single profile. Thus, respondents may have misinterpreted “very
few” to mean an amount less than ”half as many.” This misinterpretation was not
detectable through cognitive interviewing and pre-testing, but became discernible
once responses were analyzed in aggregate. Regardless of the lack of monotonicity,
the lung infection attribute was perceived as an important benefit.
Overall, greater importance reported towards the benefits relative to the risks
demonstrates favorable benefit-risk profile, such that people are likely to accept the
risks of diarrhea and blood monitoring in exchange for the benefit of maintaining
cough strength and decreased lung infection. This finding should be considered with
an understanding that the attributes and levels represented in this study do not
directly reflect the phase III clinical trial outcomes. Similarly, the inclusion criteria
for the survey do not mirror the inclusion criteria for clinical trial participants. This
was not a limitation, but rather a strategy undertaken so that the stated-preference
survey results would inform regulators about meaningful benefits-risk tradeoffs in
a broader population.
5.6 Conclusion
The results demonstrate a strong preference for therapies with a pulmonary benefit
and willingness to trade-off risks and burden to achieve these benefits. Specifically,
in exchange for maintaining cough strength for 10 years, respondents are willing to
tolerate high probabilities of diarrhea and the burden of additional blood draws.
Incorporating patient preferences into benefit-risk assessment at the regulatory
level is important for patient-centered drug development. The implications are
highly relevant in a rare disease context like DBMD because many decisions are
preference-sensitive, in part due to the high degree of uncertainty with regards to
the treatment outcomes. Furthermore, patient preference information can highlight
potential differences in views between clinicians and patients, something that is
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also more likely among rare diseases because reviewers likely have limited clinical
exposure to the disease.
The future of patient-centered drug development is in the power of quantifiable,
scientific preference data to complement efficacy data. This study demonstrates the
capacity of community-engaged preference research to provide data about variables
that are meaningful to patients and families. Furthermore, it demonstrates the
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6.1 Abstract
Background Through Patient-Focused Drug Development, the US Food and Drug
Administration (FDA) documents the perspective of patients and caregivers and
are currently conducting 20 public meetings on a limited number of disease ar-
eas. Parent Project Muscular Dystrophy (PPMD), an advocacy organization for
Duchenne muscular dystrophy (DMD), has demonstrated a community-engaged
program of preference research that would complement the FDA’s approach. Our
objective was to compare two stated-preference methods, best-worst scaling (BWS)
and con-joint analysis, within a study measuring caregivers’ DMD-treatment pref-
erences.
Methods Within one survey, two preference-elicitation methods were applied to 18
potential treatments incorporating six attributes and three levels. For each treat-
ment profile, caregivers identified the best and worst feature and intention to use
the treatment. We conducted three analyses to compare the elicitation methods
using parameter estimates, conditional attribute importance and policy simulations
focused on the 18 treatment profiles. For each, concordance between the results
was compared using Spearman’s rho.
Results BWS and conjoint analysis produced similar parameter estimates (p <
0.01); conditional attribute importance (p < 0.01); and policy simulations (p <
0.01). Greatest concordance was observed for the benefit and risk parameters,
with differences observed for nausea and knowledge about the drug-where a lack of
monotonicity was observed when using conjoint analysis.
Conclusions The observed concordance between approaches demonstrates the re-
liability of the stated-preference methods. Given the simplicity of combining BWS
and conjoint analysis on single profiles, a combination approach is easily adopted.
Minor irregularities for the conjoint-analysis results could not be explained by ad-
ditional analyses and needs to be the focus of future research.
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6.2 Background
Duchenne muscular dystrophy (DMD) is a rare neuromuscular disorder that occurs
in 1.3-2.9 per 10,000 males [1-4]. Despite the burden of the disease [5-9], treatment
is limited to off-label use of corticosteroids as there are no US FDA-approved ther-
apies [1, 10-12]. This said, several potential therapies are under investigation [12,
13]. To inform regulatory review of these therapies, Parent Project Muscular Dys-
trophy (PPMD), an advocacy organization focused on finding a cure for DMD,
led several collaborative efforts to advance regulatory science and decision making
[14, 15]. This included applying stated-preferences methods to quantify caregiver
preferences for benefits and risks [19]. Subsequently, PPMD submitted a patient-
initiated FDA draft guidance for DMD in June 2014 that includes an engagement
framework and guidance on the use of stated-preference methods to inform drug
development and regulatory review [15]. These efforts are complementary with
the FDA’s effort to integrate the patient perspective in its drug development and
approval process [16, 17]. The Patient Drug User Fee Act (PDUFA) V provides
resources for dedicated review of patient input to extend patient influence beyond
an advisory capacity [16]. The FDA initiated patient and caregiver engagement ac-
tivities through a commitment to obtain the patient perspective, through Patient-
Focused Drug Development public meetings, on 20 disease areas during the course
of PDUFA V [16]. DMD was not one of the disease areas chosen, but the FDA
noted that there are many more disease areas than can be addressed during the
public meetings, and encouraged stakeholders to generate patient/ caregiver input
on their disease area that is relevant to the PDUFA commitments [18]. They have
also sought expert guidance on measurement techniques for quantifying preferences
[17].
PPMD responded to the FDA’s encouragement to generate input through their
community-engaged research program on DMD treatment preferences. Specifically,
PPMD developed a framework for feasible community- engaged benefit-risk assess-
ment that included best-worst scaling (BWS) [19]. BWS is a recently developed
method that is used with increasing frequency in health research [20-28]. Here
we aim to compare this approach with conjoint analysis, a more common stated-
preference technique [29]. Specifically, we used a simple form of conjoint analysis
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that asks respondents if they would accept each of the profiles shown in the BWS
experiment.
In BWS, respondents are asked to consider a profile and to select the best and
the worst attribute [30]. There are different variations of BWS. A BWS object
case (case 1) assesses relative preferences for a series of items that could otherwise
be evaluated with a rating scale [30]. A BWS profile case (case 2) asks respon-
dents to evaluate one profile at a time and therefore offers greater comparability
to discrete-choice experiments or choice-based conjoint analysis [30]. Regardless of
type, collecting two responses (best and worst choice) elicits more data about the
respondent’s preferences for items than can be obtained through conjoint analy-
sis, which asks respondents to accept or reject a given commodity under a set of
conditions [31]. The essential assumption is that the choice of the best and worst
item represents the farthest difference between the degree of importance among
any items on an underlying ranking of item importance [32]. BWS places greater
emphasis on item importance, whereas conjoint analysis emphasizes trade-offs and
more closely represents a real decision [33].
Previous studies have validated preference elicitation methods against a conjoint
analysis task [32, 34]. Past studies comparing BWS and more established prefer-
ence elicitation methods report mixed results [35-38]. Comparisons have found that
the BWS object case has advantages over other methods such as superior discrimi-
natory power without additional respondent burden and higher predictive validity
[36]. An empirical comparison of BWS profile case and other discrete-choice exper-
iments demonstrates that both methods produce similar preference patterns when
rescaled [38]. To the best of our knowledge, there have been no empirical compar-
isons of a BWS profile case and a simple conjoint analysis where the respondent
can accept or reject (i.e., opt out) a treatment.
In the experiment, we aimed to determine the acceptance of clinically relevant
treatment options with varying levels of benefits and risks. By including BWS and
a conjoint analysis experiment, we aimed to exploit the complementary strengths
of both types of experiments [39]. Specifically, incorporating the conjoint analysis
question is useful because the BWS is limited in that it provides no information
about preference for a given therapy [39]. The addition of the conjoint analysis
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question provides a second analysis that supports our BWS analysis, while also pro-
viding important independent data and psychological benefits to the respondents
through asking about the most relevant endpoint–intention to use the treatment.
The objective of this paper is to compare BWS and conjoint analysis to determine
whether they produce similar results and to determine whether a combination ap-
proach is feasible and useful for quantifying benefits and risks in the context of
treatment preferences. This has the potential to contribute both to the method-
ological literature on using BWS in health and to advancing our understanding of
treatment preferences for rare disorders.
6.3 Methods
The study was conceptualized and designed by a collaborative team consisting of
members of PPMD and a team of academic collaborators [19]. The study was
part of a larger effort intended to explore DMD-related worries and preferences
for treatment options among caregivers of children with DMD. The components to
the study included a BWS experiment for analysis of worry prioritization (object
case) and an experiment that included both conjoint analysis of therapy acceptance
and BWS for measuring treatment preferences (profile case). The former is not
described here.
The study, which was reviewed and deemed exempt by the Western Institutional
Review Board, drew from a sample that was recruited using PPMD and Duchenne-
Connect, a disease-specific patient registry for patients with DMD. In addition,
snowball recruitment was used. Study participants were eligible if they were aged
at least 18 years, a caregiver for at least one child living with DMD, living in
the USA, and able to complete an online survey in English. The survey included
basic demographic questions about the caregivers and affected children, including
a disease progression item that represented impact of the disease on the child’s
function.
Experimental Design
Using a community-engaged approach, the research team identified six relevant
treatment attributes, or categories of characteristics (shown in Table 6.2), each
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with three levels. The levels indicate varying degrees of change to represent no
increased risk, mild to moderate risks, or severe risks; and no change, modest
change, and moderate change in benefit [19]. The development of the attributes
and levels was informed by multiple stakeholders, an oversight group, and the study
team. Additional details on this community-engaged, multi-stakeholder approach
have been previously published [19]. The final selection of attributes and levels is
reasonable considering the current pipeline of potential DMD therapies, with the
exception of the highest risk levels that represent much greater risk than what has
been associated with therapies in trial.
We systematically designed each of the hypothetical treatment options to vary
among three levels across the six attributes to form a BWS experiment (profile
case) [40]. We applied a 36 main effects orthogonal design, identified from the SAS
database of orthogonal arrays [41]. Orthogonal designs focus on statistical efficiency
and are commonly used and accessible methods [42, 43]. The minimum number of
treatment profiles necessary to ensure no correlations between the attributes was
18 [44].
We presented the 18 potential treatment profiles in the experiment such that
each treatment profile could be considered separate from the rest. We elicited
treatment preference using BWS by asking caregivers what parts of each treatment
profile they considered to be the best and the worst. For each treatment profile,
immediately following the BWS choice task, we asked the respondents an additional
conjoint analysis choice question–if they would use the treatment for their child if
it were available (and under the hypothetical scenario of no out-of-pocket costs and
the treatment being provided by their physician rather than as part of a clinical
trial). Their choice set for answers were “yes”, “no”, and “don’t know.” Figure
6.1 illustrates an example of the paired BWS and conjoint analysis task from the
survey instrument.
Statistical Analysis
We ran three types of analyses to compare the result from the two elicitation
formats. Specifically, we compared all parameter estimates and the conditional
attribute importance, and conducted comparative policy analysis.
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First, we calculated parameter estimates for each level of each attribute, facili-
tated by effects coding the data. In the BWS analysis, we used conditional logistic
regression, with the dependent variable as the participants’ choice of best and worst
feature of each profile, again using effect coding [21]. Using logistic regression for
the conjoint analysis, the dependent variable was the participant’s choice to accept
or reject the therapy represented by the treatment profile. We analyzed the re-
spondent’s choice set dichotomously by combining “no” and “don’t know” into one
response group. There is no consensus on the use of a “don’t know” response in
discrete-choice experiments, but this conservative approach is reasonable because,
in a real-world scenario, indecision defaults to rejection; and in an experimental
setting when forced to choose, respondents resort to “no” [45, 46]. We analyzed the
data using robust standard error to account for clustering at the individual level.
To illustrate concordance, we both reported and plotted the parameter estimates
to visually examine the patterns. Given the natures of the respective regressions
for the BWS and conjoint analysis data, it is important to note that the results
are on different scales. Rather than normalize these scales, we compared these
estimates using Spearman’s rho (although Pearson’s rho gives similar, if not more
convincing, results).
Second, we estimated conditional attribute importance for both methods by
calculating the difference between the highest and lowest parameter estimates for
each attribute and dividing it by the sum of all differences. Calculating the im-
portance of each attribute is a function of the levels chosen within the experiment,
rather than being more generalizable. This said, both elicitation formats in this
study used the same profiles, defined across the same level, and hence offer a valid
method for comparison. Again, the relative concordance between the two sets of
conditional importance was compared using Spearman’s rho.
Finally, we conducted comparative policy analysis across the 18 profiles that
were presented in the choice tasks. For the conjoint analysis, we simply used the
probabilities that caregivers accepted each of the 18 profiles. These probabilities
would provide an indication of intention to use particular drugs, which provides
practical and policy-relevant information. For the BWS, we calculated “net utili-
ties” for each treatment profile from the BWS experiment. These represent overall
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value of an entire profile rather than for an individual item. To calculate net util-
ities, we applied the BWS item parameter estimates from the regression results
and applied them to the items making up each treatment profile. The sum of
the parameter estimates for each treatment profile represents the net utility for
that treatment profile. These net utilities were compared with the probabilities of
acceptance using Spearman’s rho.
6.4 Results
Excluding five caregivers who did not complete the experiment, the final analytic
sample consisted of the 119 caregivers who completed the entire survey. The mean
age of survey respondents was 43.7 years (standard deviation [SD] 7.7), and most
were biological mothers looking after one affected child living in the home. Care-
givers also tended to be highly educated and high-income earners, with 68% of
the sample having at least a college degree and almost half of the sample (47 %)
having an income of over $US 100,000 per year. More than 90 % reported that
their child had participated in clinical research or a clinical trial. See Table 6.1 for
characteristics of participants and affected children.
Results of the BWS experiment using best-minus-worst scoring (maximum dif-
ference) have been published previously [19]. For comparison purposes with con-
joint analysis (see Table 6.2), we present BWS results using conditional logit anal-
ysis, the results of which are relatively consistent with the best-worst scaling re-
sults [19]. Overall, the parameter estimates from the two elicitation formats were
concordant (Spearman′sρ = 0.907; p < 0.01). Figure 6.2 presents a graphical
representation comparing preference weights across the two methods.
Table 6.3 presents the conditional attributes importance for each attribute,
using both BWS and conjoint analysis. The conditional attribute importance was
27 % for stopping/ slowing the progression of weakness across both studies, 21
and 23 % for risk of bleed, and 21 and 24 % for risk of heart arrhythmia for
the BWS and conjoint analysis experiments, respectively (see Table 6.3). The
conditional attribute importance was concordant across BWS and conjoint analysis
(Spearman′sρ = 0.943; p < 0.01).
Finally, the concordance between BWS and conjoint analysis was again con-
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Table 6.1: Characteristics of participants and affected child(ren) (n = 119).
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Table 6.2: Comparison of parameter estimates based on best-worst scaling and
conjoint analysis results.
Figure 6.2: Comparison of best-worst scaling and conjoint analysis results.
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Table 6.3: Comparison of conditional attribute importance.
firmed through comparative policy analysis, and rank ordering was concordant
(p < 0.01). As seen in Table 6.4, the four treatment profiles with the highest net
utilities all had a probability of acceptance greater than 80 % from the conjoint
experiment. This concordance demonstrates the complementary nature between
the two methods. It is clear that the net utility estimates for a given treatment
profile, derived from the BWS parameter estimates, corresponds to the probability
of intention to accept a specific therapy. Similarly, the four profiles with the lowest
net utilities all had a probability of acceptance less than 20 % from the conjoint
experiment.
Table 6.4: Comparative policy analysis.
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6.5 Discussion
We evaluated the concurrent use in the same survey of a conjoint analysis experi-
ment with a BWS experiment, and compared the results. Our data indicate that
the two methods are concordant, particularly in terms of individual item parameter
estimates for the benefits and risks (see Fig. 2), conditional attribute importance
(see Table 6.3), and net utility of treatment profiles compared with probabilities
of accepting the treatment (see Table 6.4). The items with the highest and lowest
utility are remarkably consistent across methods, and the treatment profiles most
and least accepted are concordant with the treatments with the highest and lowest
net utility.
We observed some important differences using the two methods. This is most
apparent when looking at the parameter estimates for the attributes “knowledge
about the drug” and “nausea”, in which the graph (Fig. 2) is not monotonic but
changes direction. The highest-level benefit for “knowledge about the drug” (2
years of post-market information) has a part-worth utility observed using BWS
of 0.30 (p < 0.05), while using conjoint analysis it is -0.19 (p < 0.05). For the
lowest level of “nausea” (none), the observed part-worth utility for BWS is 0.71
(p < 0.05), and for conjoint analysis it is -0.18 (p < 0.05). In these two instances,
the rank order of attribute importance flips (Table 6.3). We conducted two post
hoc analyses (stratified analysis based on disease severity and two-group latent class
analysis to identify subtypes based on associations with the responses) to attempt
to explain the heterogeneity in item acceptance. Disease severity was defined in
terms of ambulation status, in which children were considered to be ambulatory
if they could walk independently outdoors for short distances (such as to the car)
or if they were too young to walk. The lack of monotonicity for these two items
in the conjoint analysis could not be explained by post hoc analysis, leading us to
assume that it was due to an unobserved framing effect, where participants may
have reacted to a particular choice in different ways depending on whether it was
presented as a loss or as a gain.
Alternatively, the differences between the two methods indicate that, while re-
spondents value knowledge about the drug and nausea, these variables may not
impact the actual choices that caregivers may make. Future research should eval-
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uate differences between these two methods, and across other elicitation methods
such as more traditional paired-profile conjoint analysis methods.
The data on the intention of caregivers to accept or reject particular treatments
not only provided complementary data to BWS, but also relevant information for
industry and regulators regarding the proportion of caregivers who might use ther-
apies with different benefit-risk profiles. The results suggest that a large percentage
of parents anticipate using a drug that would stop the progression of weakness, even
given a loss of appetite and occasional vomiting together with an increased risk for
mild bleeds. In contrast, about one-third anticipate using a drug that includes two
serious risks, even given the highest benefits (stops progression and 5-year gain
in lifespan). Less than 20 % anticipate using a drug that offers a 2-year gain in
lifespan with no benefit to weakness, when associated with one serious risk.
The next phases of PPMD’s ongoing preferences studies will allow us to address
some of the limitations associated with this study. This sample of caregivers tended
to be highly educated and earning high incomes. Future research will utilize large
samples of a more diverse group of caregivers to be adequately powered for adjusted
logistic regression models and to investigate the heterogeneity in the sample. In
this study, presenting the BWS experiment before the conjoint analysis experiment
may have affected the results, as may the order of presentation for the treatment
options and attributes/levels. In future research, we can randomize the order of
the experiments and the presented treatment options.
A potential limitation of conjoint analysis is that it is subject to ceiling or floor
effects. However, we calculated the probabilities that caregivers would accept or
reject a therapy given a particular treatment profile. As seen in Table 6.4, the
variability in probability of taking the treatment across treatment profiles, and
the fact that no treatment was universally accepted or rejected, indicates that
caregivers responded to the experiment reasonably and made appropriate trade-
offs when considering their choice.
A final limitation is that we compare BWS using the conditional logit analytic
approach, which is more computationally intensive than the maximum difference
analytic approach. Previously we analyzed the data using both approaches [21,
47], and, since they are highly correlated [20, 26], we presented results from the
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more accessible maximum difference approach [19]. Given that we conducted the
BWS analysis two ways, rescaled the parameters and calculated correlations to find
the two analytic approaches to BWS to be virtually identical [19], we felt confident
that using the conditional logit analytic approach for comparing BWS with conjoint
analysis would not qualitatively change the results.
6.6 Conclusions
This study demonstrates the concordance in the preferences estimated via two
stated-preference techniques, BWS and a simple conjoint analysis. Substantively,
this provides important confirmation of our previously published results on care-
givers’ benefit-risk trade-offs for DMD therapies. The combination of BWS and
conjoint analysis experiments in a single survey is a useful approach because it
allows for the interpretation and application of the data to understand risk toler-
ance, meaningful benefits, and explore intention to use specific therapies. Our data
support the utility of this combination approach for treatment preferences research
that is intended to inform regulatory decision making.
These results and the method we propose have important implications for
patient-centered drug development. Experiments using BWS together with con-
joint analysis might be especially useful in quantifying patient and caregiver pref-
erences. These combined experiments produce results that inform sponsors, regu-
lators, and the broader rare disorder community. They are especially important in
the case of progressive, life-threatening conditions with limited treatment options,
where regulators may be less able to imagine how a “typical” patient or caregiver
might weigh benefits and risks. The ongoing benefit-risk research led by PPMD
demonstrates that patient and disease advocacy groups can contribute to the lit-
erature on benefit-risk, while also providing leadership in furthering community-
centered approaches and scientific methodologies to advance the FDA’s commit-
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7.1 Summary of findings
The first key finding of this work is the demonstration of a successful process for
engaging the community in survey development. The engagement process was crit-
ical for identifying appropriate eligibility criteria, refining attributes for the survey
and revealing the delicate nature of mapping clinical trial endpoints to meaningful
survey objects (Chapter 3). The second key finding of this dissertation is that
caregivers and patients did not differ in their priorities for signs and symptoms
to be targeted by therapeutic interventions. Both groups favored targeted cardiac
and pulmonary symptoms such as weaker heart pumping, cough strength and fre-
quency of lung infections. The lowest priority symptom was poor attention span.
Chapter 4 findings indicate the existence of heterogeneity among priorities, al-
though the differences may be related to unobserved characteristics. In Chapter
5, findings reveal patients were willing to accept significant risk for moderate im-
provements in pulmonary decline. Specifically, in exchange for maintaining cough
strength for 10 years, respondents were willing to tolerate high probabilities of di-
arrhea and additional blood draws. Although not powered to detect statistically
significant differences, there were no qualitative differences in preferences between
caregivers and patients. Again, heterogeneity was present for these preferences.
Finally, methodological findings in Chapter 6 indicate that a follow-up question in
best-worst scaling surveys about intention to use a particular therapy adds useful,




There are implications for this dissertation that are specific to Duchenne mus-
cular dystrophy as well as the broader rare disease community. First, for the
Duchenne muscular dystrophy community this dissertation measures patient prior-
ities, which contributes to the overall body of knowledge around patient preferences
in Duchenne muscular dystrophy and as a result improves the usefulness of future
development. It also quantifies patient preferences for a pulmonary benefit, in-
formation that will be incorporated into regulatory review and may contribute to
an outcome that meets the community’s needs. Second, the implications for the
broader rare disease community are that a model exists for how rare diseases can
undergo this research. It also brings to light the ways that preference information
can be incorporated into other policy research areas relevant to rare diseases such
as advancing research and ensuring access to treatments. This research also under-
scores the importance of preference work in the rare disease community specifically
because of its unique needs.
Furthermore, this dissertation advances the body of research related to stated-
preferences more generally. This research provides a model for how industry and/or
advocacy organizations can conduct stated preference studies to contribute to
patient-focused drug development. In Chapter 3, I demonstrate a process for how
industry, advocacy, and methodological experts can collaborate with the patient
community to design a patient-centered survey. In Chapter 4, I demonstrate how
patient preference information can be collected to inform early stages of drug de-
velopment such as needs assessment and can contribute to a body of knowledge on
patient preferences. In Chapter 5, I demonstrate how patient preferences can be
quantified to directly inform patient-centered benefit-risk assessment. In Chapter
6, I demonstrate that these methods are feasible and accessible, and that they pro-
duce the right information required to inform regulatory review. This dissertation
as a whole paves the way for future innovators to study, and incorporate patient
preferences into drug development work.
Providing this information to the FDA and continuing to emphasize the im-
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portance of patient preferences in the decision-making process may exert pressure
on the FDA to consider preference data as an important part of regulatory review.
In an ideal case, the FDA will formally incorporate preference information into
the benefit-risk framework, requiring it as part of their regulatory review process
for preference sensitive conditions. This could have tremendous potential spillover
effects due to the global economic and scientific reach of the FDA’s power [1]. The
FDA’s power, derived from its regulation of the entry into the US pharmaceuti-
cal marketplace, positions the FDA to play a pivotal role in advancing patient-
centeredness and have widespread influence in patient-centered drug development
around the world.
Patient preference methods require expertise and are expensive and time con-
suming. Therefore these methods may need to be reserved for situations with the
greatest degree of uncertainty, complexity or contention [2]. Furthermore, these
methods aren’t easily scalable or generalizable. However, there is a role for patient
preferences in each phase of the drug development life cycle and patient-focused
drug development has the potential to impact a variety of stakeholder [3].
We demonstrated how preference information can contribute to the discovery
and ideation phase (Chapter 4) and to the regulatory review phase (Chapter 5).
There is room for future work around preference information in the clinical trial
phase, specifically related to end-point selection. Preference information in benefit-
risk assessment in the post-marketing phase will be an important part of future
work as well. As we learn about the drugs from post-market surveillance, benefit-
risk information must be updated [4]. The context surrounding benefits and risks
may change as well. For instance a drug may go from being the only available option
to one of many. Another important aspect of post-market research may be related
to comparative effectiveness research and how individual patient preferences may
be used to aid in their decision-making at the clinical encounter level. Future re-
search opportunities include shared-decision making tools that incorporate patient
preference information into a personal benefit-risk assessment.
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ADULT PATIENT VERSION OF BENEFIT-RISK SURVEY 
 
This survey is an experiment to learn about your priorities and preferences about 
treatments for Duchenne and Becker muscular dystrophy (DBMD). This survey is for 
adults with DBMD who are over 18 years old. There is another version of the survey for 
your parent and a version of the survey for adults with DBMD to answer. Click here if 
you are not a teen and want to see links to other versions of the survey.                          
 
In this survey you will read about treatments for DBMD. Some parts of the treatments 
used in this survey are real but other parts are made up. This information is important to 
help the FDA and others understand your thoughts and feelings about potential future 
DBMD treatments. 
 
It is possible that these questions might make you feel upset because they deal with the 
effects of DBMD on the body. It is your choice to answer the survey. You can stop taking 
the survey at any time. The survey information is anonymous, meaning that no one 
knows who participates and what answers they give. 
 
The survey takes about 1 hour. As long as you use the same computer, you can answer 
some of the questions and take a break (your answers will be saved) and go back to the 
survey later. There are no right or wrong answers; we ask you to share your honest 
opinions and feelings. If you have questions or concerns about this survey, please 




1. Are you 18 years of age or older? YES / NO 
 
2. Do you have Duchenne or Becker muscular dystrophy? YES / NO 
 
3. Do you live in the United States? YES / NO 
 
If answer to any of the above in No… 
Thank you for your interest, but you do not qualify for the study. If you would like 
to access the version of the survey for parents, please Click here. If you would 
like to access the version for teens with DBMD please Click here.  
Click here to exit survey.  
 
4. Taking this survey is your choice. You can stop taking the survey at any time. If 
you agree to participate, please click the Yes button. If not, click the No button. 
YES / NO 
 
If No… 




First, please answer a few questions about yourself. 
 
1. How old are you? [Pull down menu with younger than 18 disqualified] 
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b. Married or long-term committed relationship 
c. Divorced or separated 
d. Widowed 
 
3. Are you Hispanic or Latino? YES / NO 
 
4. Which of the following racial groups best describes you? (please select all that 
apply) 
 
a. American Indian or Alaskan Native 
b. Asian 
c. Black or African American 
d. Native Hawaiian or Other Pacific Islander 
e. Hispanic or Latino 
f. White 
g. Other: please specify _________________ 
 
5. What is the highest level of education you have completed? (select only one 
answer) 
 
a. Less than some high school 
b. Some high school 
c. High school or GED 
d. Some college but no degree 
e. Technical School (currently enrolled or completed) 
f. Associate’s Degree (2-year college degree) 
g. 4-year college degree (e.g., BA, BS) 
h. Some graduate school but no degree 
i. Graduate or professional degree (e.g., MBA, MS, MD, PhD) 
 
6. What is your annual household income? 
 




e. More than $100,000 
f. Prefer not to answer 
 
7. What state do you live in? [pull-down menu] 
 
8. What is your diagnosis? 
 
a. Duchenne muscular dystrophy 
b. Becker muscular dystrophy 
c. Intermediate muscular dystrophy 
d. I don’t know 
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9.  Choose the option that best describes your physical abilities. Everyone is unique, 
and you may not match the descriptions perfectly. Please select the answer that 
is the best fit. I usually:  
 
a. Walk independently for long distances outdoors (more than 1⁄2 mile)  
b. Walk independently for less than 1⁄2 mile, but more than short distances  
c. Walk independently outdoors for short distances (such as to the car)  
d. Walk outdoors with help from a person 
e. Walk independently indoors but needs a wheelchair for outdoors  
f. Walk indoors with help from a person but need a wheelchair for outdoors  
g. Use wheelchair and can go indoors and outdoors  
h. Use wheelchair but unable to go outdoors in some situations (such as 
cold weather)  
i. Unable to control wheelchair without help  
j. Not using wheelchair. Remain in bed. 
 
10. Have you ever used corticosteroids? 
 
a. Currently using prednisone/prednisolone 
b. Currently using deflazacort 
c. Used to take corticosteroids but not anymore  
d. Never used corticosteroids  
e. I do not know 
 
11. What type of health insurance do you use for medical care? (select all that apply)  
 
a. Private Health Insurance  
b. State/government program, such as Medicaid/Medicare  
c. No insurance 
d. Other (please specify) 
_____________________________________________ 
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Section 1: Signs & Symptoms to be Treated 
 
Think about new treatments for Duchenne and Becker muscular dystrophy (DBMD). The 
treatments would not be a cure but could help reduce the effects of DBMD. First, we will 
describe a number of signs and symptoms. Then we will ask you to give your opinion 
about what signs and symptoms are most important to you in developing new 
treatments.  
 
These are signs and symptoms that often become more problematic as people with 
DBMD get older. Read the descriptions of the signs and symptoms below. First we will 
ask you to answer some questions about your experience with each symptom. Then, in 
the first task, you will answer more questions to see which symptoms are most important 
to you.  
 
Here are the signs and symptoms that are used in the task. 
[The online survey randomizes the order in which these are presented] 
 
Weaker ability to cough: As DBMD progresses and with decline in respiratory 
function, the ability to cough forcefully may be lost. A strong cough is important for 
clearing the airway and letting the person get a good deep breath. Some people use 
devices (such as cough assist, BIPAP or CPAP) to help them cough or breathe 
better. 
 
Have you ever used cough assist, BiPAP, CPAP, or had a tracheostomy? 
YES / NO 
 
Lung infections: Getting an infection in the lungs requires going to the doctor and 
taking antibiotics. Serious infections like pneumonia have to be treated in the hospital 
and might make it harder for the lungs to work well over time. 
 
Have you ever been treated for pneumonia? YES / NO 
 
Weaker heart pumping: Over time, people with DBMD’s hearts can’t squeeze as 
strongly as they used to. This means that they have to take heart medicines to help 
the heart pump. 
 
Do you take any heart (cardiac) medication? YES / NO 
	  
Frequent waking at night: Teens and adults with DBMD may have more trouble 
sleeping soundly through the night, partly due to decline in lung function. People with 
this problem may need more help from caregivers to sleep comfortably.  
 
In the past 7 days, I had trouble staying asleep…  
Never / Rarely / Sometimes / Often / Always 
 
Bone fractures: Bones can become weaker once a person with DBMD stops 
walking, and also from taking steroids. Weak bones lead to an increased chance of 
broken bones. 
 
Have you had any broken bones (bone fractures)? YES / NO 
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Constipation: People with DBMD may have trouble with constipation (going more 
than 2 days without a bowel movement) due to immobility or medication side effects. 
 
In the past 7 days, how often did you have a bowel movement? 
2 times or less / 3 to 6 times / Once a day / 2 to 3 times a day / More than 3 
times a day 
 
Headaches: Most people get headaches every once in a while. But frequent bad 
headaches can become more common in teens and adults with DBMD and may be 
caused by poor respiratory functioning.  
 
During the past 7 days, how many headaches have you had? 
2 times or less / 3 to 6 times / Once a day / 2 to 3 times a day / More than 3 
times a day 
 
Feeling tired: After they wake up and throughout the day, people with DBMD may 
have more trouble with feeling tired than other people (also known as “daytime 
sleepiness”). 
 
In the past 7 days how often have you felt tired? 
Never / Almost never / Sometimes / Often / Almost always 
 
Non-healthy weight: People with DBMD can have trouble with gaining enough 
weight, while others have the problem of gaining too much weight. 
 
Which best describes your weight?  
Weigh too much / Healthy weight / Weigh too little 
 
Poor attention span: Some people with DBMD experience more problems with 
paying attention and staying focused on a task than other people. 
 
Do you have difficulty concentrating and focusing during the day? 
Never/Almost Never / Sometimes / Often / Almost always  
 
Depression: Living with DBMD may increase the chance for symptoms of 
depression, such as feeling sad, irritable, or not being interested in activities. 
 
In the past 7 days how often could you not help feeling sad? 
Never / Almost never / Sometimes / Often / Almost always 
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Task 1. 
 
It’s time for the first preference task. Keep in mind the descriptions of the symptoms that 
you just read. In each of the lists below, which of these symptoms are the most 
important for new treatments to improve? Which are the least important?  
 
Your answers should be based on your own opinion and experiences. This is not a test. 
There are no right or wrong answers. 
 
Here is an example: 
 




Most important to 
treat 
Least important to 
treat 
A Headaches O O 
B Depression O O 
C Feeling tired X O 
D Constipation O O 
E Poor attention span O X 
 
Mike looks at the items in the list: headaches, depression, feeling tired, constipation, and 
poor attention span. He has to choose which symptom is the MOST important for a new 
treatment to improve and which is the LEAST important to improve. Based on his own 
experience and opinion, Mike thinks that “feeling tired” is the most important, so in the 
“Most important to treat” column he clicks the circle next to “feeling tired.” He thinks that 
“poor attention span” is the least important to treat, so in the “Least important to treat” 
column he clicks the circle next to “poor attention span.” Mike finds this difficult because 
he actually thinks that all of these are important, but he is able to make a choice.  
 
[on each screen: Choose the most important symptom for a new treatment to improve by 
clicking the circle under “Most important to treat” and choose the least important 
symptom by clicking the circle under “Least important to treat.” You have to choose a 
most important and a least important item to move on.] 
    
1   
Most important to 
treat 
Least important to 
treat 
A Feeling tired O O 
B Depression O O 
C Weaker ability to cough O O 
D Bone fractures O O 
E Poor attention span O O 
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2   
Most important to 
treat 
Least important to 
treat 
A Headaches O O 
B Poor attention span O O 
C Depression O O 
D Frequent waking at night O O 
E Non-healthy weight O O 
 
 
   
3   
Most important to 
treat 
Least important to 
treat 
A Frequent waking at night O O 
B Headaches O O 
C Feeling tired O O 
D Weaker ability to cough O O 





4   
Most important to 
treat 
Least important to 
treat 
A Weaker heart pumping O O 
B Constipation O O 
C Headaches O O 
D Depression O O 
E Bone fractures O O 
    
5   
Most important to 
treat 
Least important to 
treat 
A Weaker ability to cough O O 
B Frequent waking at night O O 
C Bone fractures O O 
D Non-healthy weight O O 
E Weaker heart pumping O O 
    
6   
Most important to 
treat 
Least important to 
treat 
A Lung infections O O 
B Bone fractures O O 
C Constipation O O 
D Poor attention span O O 
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7   
Most important to 
treat 
Least important to 
treat 
A Bone fractures O O 
B Feeling tired O O 
C Non-healthy weight O O 
D Lung infections O O 
E Headaches O O 
    
8   
Most important to 
treat 
Least important to 
treat 
A Constipation O O 
B Non-healthy weight O O 
C Poor attention span O O 
D Weaker heart pumping O O 
E Feeling tired O O 
    
9   
Most important to 
treat 
Least important to 
treat 
A Non-healthy weight O O 
B Weaker ability to cough O O 
C Lung infections O O 
D Constipation O O 
E Depression O O 
    
10   
Most important to 
treat 
Least important to 
treat 
A Depression O O 
B Weaker heart pumping O O 
C Frequent waking at night O O 
D Feeling tired O O 
E Lung infections O O 
    
11   
Most important to 
treat 
Least important to 
treat 
A Poor attention span O O 
B Lung infections O O 
C Weaker heart pumping O O 
D Headaches O O 
E Weaker ability to cough O O 
 
You are finished with the first task.  
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Section 2. Treatment Preferences 
 
We now describe possible treatments that are based on some qualities of a real drug. 
Because of the way this type of research is run, some of the side effects and risks in this 
survey are more serious than we expect in real life. So you will be seeing made-up 
treatments with some realistic parts and some not so realistic parts.  
    
Imagine that these are approved treatments given by your doctor, and not part of a 
clinical trial. The treatments have different benefits and risks. The average result can 
help you understand what you might expect for yourself.  
    
We describe different possibilities for the treatment below. Please read carefully. Later in 
the survey we ask you questions about these treatment possibilities.   
   
Cough Strength 
 
Taking the medicine may help slow the impact of DBMD on the ability to cough. A weak 
cough is part of the progression of DBMD as people get older and their lung function 
gets worse. A strong cough is important for clearing the airway and letting you get a 
good deep breath. Here are the ways the medicine could help your ability to cough: 
 
“Cough strength: maintained for up to 10 years” This means that your cough 
would stay as strong as it is now for an average of 10 more years. If you 
have no trouble coughing well now, you won’t have any trouble for about 10 
more years. If you have mild trouble with coughing now, it will not get worse 
for about 10 more years. If you have a weak cough now, it will not get worse 
for about 10 more years.  
“Cough strength: maintained for 2 years.” This means that your cough would 
stay at the current level for an average of 2 more years.  
“Cough strength: no benefit.” The drug would not work on your coughing at all, 




Taking the medicine may help you get fewer infections in his lungs. Getting an infection 
in the lungs means you have to go to the doctor and take antibiotics. Serious infections 
like pneumonia have to be treated in the hospital, and they might make it harder for your 
lungs to work well over time. Here are ways that the medicine could help with lung 
infections: 
  
“Lung infections: very few.” After you start taking the drug, you would get lung 
infections very rarely, if at all, for your whole life. 
“Lung infections: half as many.” After you start taking the drug, you would get 
about half as many lung infections compared to if you did not take the drug. 
“Lung infections: no benefit.” The drug would not affect how often you get 
lung infections. 
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Mild Diarrhea 
 
Because of taking the medicine you may get mild diarrhea. This means that you have 2 
to 4 more bowel movements a day, but you do not have to go to a doctor for it. The 
diarrhea may last only a few days. Taking the medicine may cause: 
  
No (or 0%) extra chance you will get diarrhea.  
1 out of 5 (or 20%) chance you will get diarrhea.  




Because of taking the medicine, for the whole time you are treated you will have to 
have blood tests for safety. Your doctor may ask for: 
 
No blood tests. This means you do not have to have any extra blood tests 
during the year. 
Blood tests 2 times a year. This means you have extra blood tests every 6 
months. 
Blood tests 4 times a year. This means that you have extra blood tests every 3 
months.  
    
Task 2. 
    
It is time to start the second task. You will see 9 different treatments. Some parts of the 
treatments used in this survey are real but other parts are made up. We are interested in 
knowing what you would choose if these treatments did exist. There are no right or 
wrong answers. Remember, we are imagining that these are approved treatments 
provided by the doctor, and not treatments given during a clinical trial. These treatments 
are in addition to any medications you currently take, and will not replace those 
medications. Please assume that all of the medical bills, including the cost of the 
treatments, are covered by health insurance. 
 
To make the task work, a computer chose a set of benefits and risks. Some of the 
treatments may not seem realistic. For example, sometimes the treatments sound bad. 
Even though this may feel wrong, it is important to make the task work. Please answer 
the questions as well as you can. 
 
Some people find this task difficult. Feel free to take a break. Nobody is going to know if 
you stop, and we want you to be comfortable. After a break you can come back to the 
survey, as long as you are using the same computer. If you have questions or concerns 
about this survey, please contact Holly Peay at holly@parentprojectmd.org. 
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Example task  
    
Here is an example. Mike is taking the survey. He sees this table describing several 
effects of the treatment. 
 
Best  Worst 
X Cough strength: Maintained for 10 years O 
O Lung infections: Half as many O 
O Mild diarrhea: 1 in 5 (20%) X 
O Blood test: 4 times a year O 
 
This table shows a treatment that has two benefits: cough strength is maintained for 15 
years, and there are half as many lung infections as expected. But there are downsides. 
There is a 20% chance of diarrhea, and people who take the drug have a blood draw 4 
times a year to test for safety. 
 
Mike has to pick the best and worst things about the drug. It was hard to pick the best 
thing, because he believes that “cough strength maintained for 10 years” and “half as 
many lung infections” are both very good. Mike clicked on the circle next to “cough 
strength: maintained for 10 years” because he decided it was best. Mike was worried 
about the “20% chance of diarrhea” and the “blood draws 4 times a year,” but he clicked 
the circle next to “20% chance diarrhea” because he thought it would be the worst thing 
about using the treatment. 
 
Now it is your turn. For each treatment we describe, choose the best and worst 
thing. Then tell us whether you think you would decide to use the treatment for 
yourself. You will find a reminder of the directions above each table.  
 
[on each screen: Choose the best thing about the treatment by clicking the circle under 
“Best” and choose the worst thing by clicking the circle under “Worst.” You have to 
choose a best and a worst thing to move on. Remember that a computer chose 
combinations to make the task work, and some of them seem bad. Even so, please pick 
the best and worst thing.  
 
There are no right or wrong answers. We are interested in your honest opinions. If you 
have questions or concerns about this survey, please contact Holly Peay at 
holly@parentprojectmd.org.] 





O Cough strength: No benefit O 
O Lung infections during your life: Half as many O 
O Your chance for diarrhea: No extra chance O 




Would you choose to use this treatment? YES / NO 
 
 Best  Worst 
O Cough strength: No benefit O 
O Lung infections during your life: Very few O 
O Your chance for diarrhea: 1 in 5 (20%) O 
O How often you need a blood test: 2 times a year O 
 
 
Would you choose to use this treatment? YES / NO 
 
 Best  Worst 
O Cough strength: Maintained for 2 years O 
O Lung infections during your life: Very few O 
O Your chance for diarrhea: 1 in 2 (50%) O 
O How often you need a blood test: 4 times a year O 
 
 
Would you choose to use this treatment? YES / NO 
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Best  Worst 
O Cough strength: Maintained for 10 years O 
O Lung infections during your life: Very few O 
O Your chance for diarrhea: No extra chance O 
O How often you need a blood test: No extra blood tests O 
 
 
Would you choose to use this treatment? YES / NO 
 
 Best  Worst 
O Cough strength: Maintained for 2 years O 
O Lung infections during your life: No benefit O 
O Your chance for diarrhea: No extra chance O 
O How often you need a blood test: 2 times a year O 
 
 
Would you choose to use this treatment? YES / NO 
 
 Best  Worst 
O Cough strength: Maintained for 10 years O 
O Lung infections during your life: No benefit O 
O Your chance for diarrhea: 1 in 5 (20%) O 
O How often you need a blood test: 4 times a year O 
 
 
Would you choose to use this treatment? YES / NO 
 
 Best  Worst 
O Cough strength: Maintained for 10 years O 
O Lung infections during your life: Half as many O 
O Your chance for diarrhea: 1 in 2 (50%) O 
O How often you need a blood test: 2 times a year O 
   
 
Would you choose to use this treatment? YES / NO 
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Best  Worst 
O Cough strength: No benefit O 
O Lung infections during your life: No benefit O 
O Your chance for diarrhea: 1 in 2 (50%) O 










O Cough strength: Maintained for 2 years O 
O Lung infections during your life: Half as many O 
O Your chance for diarrhea: 1 in 5 (20%) O 
O How often you need a blood test: No extra blood tests O 
 
 
Would you choose to use this treatment? YES / NO 
  
You are now finished with the second task. 
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Task 3.  
 
These are the last questions and they should take less than 10 minutes. In the tasks you 
just completed, we only asked for your input on a few items. There are lots of other 
benefits, side effects, and details about how a medicine is taken.  
 
Imagine a medication described below. In your own opinion, how meaningful are 
the following medication benefits and risks to you?  
[Order of items below will be randomized]. 
 
People with DBMD have progressive loss in lung function when they get older. This 
means they have to use devices like cough assist or BiPAP to support breathing during 
the day and sometimes also during the night. If the medication could slow down your 
loss in lung function for 5 more years, would this be important for you? 
 
Not at all / A little / Somewhat / Very much 
 
If the medication could maintain your ability to cough well for 5 more years, how 
important is that to you? 
 
Not at all / A little / Somewhat / Very much 
 
If the medication caused you to have fewer lung infections over the next 5 years, how 
important is that to you?  
 
Not at all / A little / Somewhat / Very much 
 
The medication comes as small, coated pills that would be taken 3 times a day. For each 
dose you would take 2 pills—a total of 6 pills each day. The medication needs to be 
taken with food and it cannot be crushed. Most people find it easy to swallow and it has 
no taste. How much of a burden is this for you? 
 
Not at all / A little / Somewhat / Very much 
 
For the whole time you take the medicine, you would need blood tests every six months 
(twice a year). How much of a burden is this for you? 
 
Not at all / A little / Somewhat / Very much 
 
Because of taking the medication, you could have mild and temporary diarrhea as a side 
effect. How much of a burden is this for you? 
 
Not at all / A little / Somewhat / Very much 
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